<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Colli, A - 2021 | Cochrane Library</title> <meta content="Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Colli, A - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Colli, A - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013346.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease" name="citation_title"/> <meta content="Agostino Colli" name="citation_author"/> <meta content="Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico" name="citation_author_institution"/> <meta content="colliagostino@gmail.com" name="citation_author_email"/> <meta content="Tin Nadarevic" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Damir Miletic" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Vanja Giljaca" name="citation_author"/> <meta content="Heart of England NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mirella Fraquelli" name="citation_author"/> <meta content="Fondazione IRCCS Ca´ Granda - Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Davor Štimac" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Giovanni Casazza" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD013346.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abdomen [diagnostic imaging]; alpha-Fetoproteins [*analysis]; Bias; Biomarkers, Tumor [blood]; Carcinoma, Hepatocellular [blood, *diagnosis, pathology]; Case-Control Studies; Chronic Disease; Confidence Intervals; Cross-Sectional Studies; Liver Diseases [*complications]; Liver Neoplasms [blood, *diagnosis, pathology]; Sensitivity and Specificity; Ultrasonography [*methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013346.pub2&amp;doi=10.1002/14651858.CD013346.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013346\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013346\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","th","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013346.pub2",title:"Abdominal ultrasound and alpha\\u2010foetoprotein for the diagnosis of hepatocellular carcinoma\\u00A0in adults with chronic liver disease",firstPublishedDate:"Apr 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013346.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013346.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013346.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013346.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013346.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013346.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013346.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013346.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013346.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013346.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6297 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013346.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/appendices#CD013346-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/table_n/CD013346StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/table_n/CD013346StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Agostino Colli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0005">Tin Nadarevic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0006">Damir Miletic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0007">Vanja Giljaca</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0008">Mirella Fraquelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0009">Davor Štimac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information#CD013346-cr-0010">Giovanni Casazza</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information/en#CD013346-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013346.pub2">https://doi.org/10.1002/14651858.CD013346.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013346-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013346-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013346-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013346-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013346-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013346-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013346-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013346-abs-0001" lang="en"> <section id="CD013346-sec-0001"> <h3 class="title" id="CD013346-sec-0001">Background</h3> <p>Hepatocellular carcinoma (HCC) occurs mostly in people with chronic liver disease and ranks sixth in terms of global instances of cancer, and fourth in terms of cancer deaths for men. Despite that abdominal ultrasound (US) is used as an initial test to exclude the presence of focal liver lesions and serum alpha‐foetoprotein (AFP) measurement may raise suspicion of HCC occurrence, further testing to confirm diagnosis as well as staging of HCC is required. Current guidelines recommend surveillance programme using US, with or without AFP, to detect HCC in high‐risk populations despite the lack of clear benefits on overall survival. Assessing the diagnostic accuracy of US and AFP may clarify whether the absence of benefit in surveillance programmes could be related to under‐diagnosis. Therefore, assessment of the accuracy of these two tests for diagnosing HCC in people with chronic liver disease, not included in surveillance programmes, is needed. </p> </section> <section id="CD013346-sec-0002"> <h3 class="title" id="CD013346-sec-0002">Objectives</h3> <p>Primary: the diagnostic accuracy of US and AFP, alone or in combination, for the diagnosis of HCC of any size and at any stage in adults with chronic liver disease, either in a surveillance programme or in a clinical setting. </p> <p>Secondary: to assess the diagnostic accuracy of abdominal US and AFP, alone or in combination, for the diagnosis of resectable HCC; to compare the diagnostic accuracy of the individual tests versus the combination of both tests; to investigate sources of heterogeneity in the results. </p> </section> <section id="CD013346-sec-0003"> <h3 class="title" id="CD013346-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Hepato‐Biliary Group Diagnostic‐Test‐Accuracy Studies Register, Cochrane Library, MEDLINE, Embase, LILACS, Science Citation Index Expanded, until 5 June 2020. We applied no language or document‐type restrictions. </p> </section> <section id="CD013346-sec-0004"> <h3 class="title" id="CD013346-sec-0004">Selection criteria</h3> <p>Studies assessing the diagnostic accuracy of US and AFP, independently or in combination, for the diagnosis of HCC in adults with chronic liver disease, with cross‐sectional and case‐control designs, using one of the acceptable reference standards, such as pathology of the explanted liver, histology of resected or biopsied focal liver lesion, or typical characteristics on computed tomography, or magnetic resonance imaging, all with a six‐months follow‐up. </p> </section> <section id="CD013346-sec-0005"> <h3 class="title" id="CD013346-sec-0005">Data collection and analysis</h3> <p>We independently screened studies, extracted data, and assessed the risk of bias and applicability concerns, using the QUADAS‐2 checklist. We presented the results of sensitivity and specificity, using paired forest‐plots, and tabulated the results. We used a hierarchical meta‐analysis model where appropriate. We presented uncertainty of the accuracy estimates using 95% confidence intervals (CIs). We double‐checked all data extractions and analyses. </p> </section> <section id="CD013346-sec-0006"> <h3 class="title" id="CD013346-sec-0006">Main results</h3> <p>We included 373 studies. The index‐test was AFP (326 studies, 144,570 participants); US (39 studies, 18,792 participants); and a combination of AFP and US (eight studies, 5454 participants). </p> <p>We judged at high‐risk of bias all but one study. Most studies used different reference standards, often inappropriate to exclude the presence of the target condition, and the time‐interval between the index test and the reference standard was rarely defined. Most studies with AFP had a case‐control design. We also had major concerns for the applicability due to the characteristics of the participants. </p> <p>As the primary studies with AFP used different cut‐offs, we performed a meta‐analysis using the hierarchical‐summary‐receiver‐operating‐characteristic model, then we carried out two meta‐analyses including only studies reporting the most used cut‐offs: around 20 ng/mL or 200 ng/mL. </p> <p><b>AFP cut‐off 20 ng/mL</b>: for HCC (147 studies) sensitivity 60% (95% CI 58% to 62%), specificity 84% (95% CI 82% to 86%); for resectable HCC (six studies) sensitivity 65% (95% CI 62% to 68%), specificity 80% (95% CI 59% to 91%). </p> <p><b>AFP cut‐off 200 ng/mL</b>: for HCC (56 studies) sensitivity 36% (95% CI 31% to 41%), specificity 99% (95% CI 98% to 99%); for resectable HCC (two studies) one with sensitivity 4% (95% CI 0% to 19%), specificity 100% (95% CI 96% to 100%), and one with sensitivity 8% (95% CI 3% to 18%), specificity 100% (95% CI 97% to 100%). </p> <p><b>US</b>: for HCC (39 studies) sensitivity 72% (95% CI 63% to 79%), specificity 94% (95% CI 91% to 96%); for resectable HCC (seven studies) sensitivity 53% (95% CI 38% to 67%), specificity 96% (95% CI 94% to 97%). </p> <p><b>Combination of AFP (cut‐off of 20 ng/mL) and US</b>: for HCC (six studies) sensitivity 96% (95% CI 88% to 98%), specificity 85% (95% CI 73% to 93%); for resectable HCC (two studies) one with sensitivity 89% (95% CI 73% to 97%), specificity of 83% (95% CI 76% to 88%), and one with sensitivity 79% (95% CI 54% to 94%), specificity 87% (95% CI 79% to 94%). </p> <p>The observed heterogeneity in the results remains mostly unexplained, and only in part referable to different cut‐offs or settings (surveillance programme compared to clinical series). The sensitivity analyses, excluding studies published as abstracts, or with case‐control design, showed no variation in the results. </p> <p>We compared the accuracy obtained from studies with AFP (cut‐off around 20 ng/mL) and US: a direct comparison in 11 studies (6674 participants) showed a higher sensitivity of US (81%, 95% CI 66% to 90%) versus AFP (64%, 95% CI 56% to 71%) with similar specificity: US 92% (95% CI 83% to 97%) versus AFP 89% (95% CI 79% to 94%). A direct comparison of six studies (5044 participants) showed a higher sensitivity (96%, 95% CI 88% to 98%) of the combination of AFP and US versus US (76%, 95% CI 56% to 89%) with similar specificity: AFP and US 85% (95% CI 73% to 92%) versus US 93% (95% CI 80% to 98%). </p> </section> <section id="CD013346-sec-0007"> <h3 class="title" id="CD013346-sec-0007">Authors' conclusions</h3> <p>In the clinical pathway for the diagnosis of HCC in adults, AFP and US, singularly or in combination, have the role of triage‐tests. We found that using AFP, with 20 ng/mL as a cut‐off, about 40% of HCC occurrences would be missed, and with US alone, more than a quarter. The combination of the two tests showed the highest sensitivity and less than 5% of HCC occurrences would be missed with about 15% of false‐positive results. The uncertainty resulting from the poor study quality and the heterogeneity of included studies limit our ability to confidently draw conclusions based on our results. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013346-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013346-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013346-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013346-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013346-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013346-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013346-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013346-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013346-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013346-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013346-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013346-abs-0002" lang="en"> <h3>Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma</h3> <p><b>Why is improving the diagnosis of hepatocellular carcinoma important?</b> </p> <p>Hepatocellular carcinoma (HCC), i.e. cancer originating in the liver, is sixth in terms of global occurrences of cancer and fourth in terms of cancer deaths in men. This cancer occurs mostly in people with chronic liver disease regardless of the cause. Ultrasound (US), which uses ultrasound waves to show abnormalities in the liver, can detect the presence of liver lesions suspected of being HCC. Alpha‐foetoprotein (AFP), a glycoprotein, produced by the liver and measurable in the blood, is considered a tumour‐marker because high levels can be associated with the presence of HCC. These two tests (US and AFP) are used, alone or in combination, to exclude the presence of HCC in people at high risk of developing HCC. People at high risk are those who have chronic liver disease. Current guidelines recommend surveillance programmes, repeating abdominal US with or without AFP testing every six months to detect early HCC, amenable to surgical resection or other treatment. </p> <p><b>What is the aim of this review?</b> </p> <p>To find out how accurate AFP, US, and a combination of AFP and US are for diagnosing HCC in people with chronic liver disease. </p> <p><b>What was studied in this review?</b> </p> <p>AFP (tumour marker), that can easily be measured in the blood, using a commercial kit. Studies with AFP used various threshold values for defining the test as positive or negative. </p> <p>US is an equipment, available worldwide. It produces images of liver and other abdominal organs. It can detect the presence of liver lesions suspected of being HCC. </p> <p>A combination of AFP and US can detect or negate the presence of liver lesions suspected of being HCC. </p> <p><b>What are the main results in this review?</b> </p> <p>We found 373 total studies in adults: AFP was analysed in 326 studies, 144,570 participants; US in 39 studies, 18,792 participants; and the combination of AFP and US in eight studies, 5454 participants. </p> <p>‐ AFP with threshold of 20 ng/mL (147 studies): the test was positive in 60 out of 100 participants with HCC and in 16 out of 100 participants without HCC. AFP with threshold of 200 ng/mL (56 studies): the test was positive in 36 out of 100 participants with HCC and only in 1 out of 100 without HCC.<br/>‐ US (39 studies): the test was positive in 72 out of 100 participants with HCC and in 6 out of 100 participants without HCC.<br/>‐ The combination of AFP with threshold of 20 ng/mL and US (6 studies): one or both tests were positive in 96 out of 100 participants with HCC and in 15 out of 100 participants without HCC. </p> <p>Thus, the combination of the two tests is better in detecting participants with HCC. Considering that people with chronic liver disease have HCC in 5 out of 100, one can assume that among 1000 people with chronic liver disease, 50 will have HCC, and, using AFP and abdominal US in combination, one can detect 48 out of the people with HCC, and 2 people will go undetected and will not receive appropriate treatment; 950 out of 1000 will have no HCC, and 143 of them will receive a wrong diagnosis of HCC, and will undergo further unnecessary testing such as computed tomography, magnetic resonance imaging, or biopsy. </p> <p><b>How reliable are the results of the studies in this review?</b> </p> <p>All but one study had issues with risk of bias, especially in participants selection and in the correct definition on presence of HCC. These problems could impair the correct estimates of the diagnostic ability of the three tests. </p> <p><b>Who do the results of this review apply to?</b> </p> <p>People with chronic liver disease</p> <p><b>What are the implications of this review?</b> </p> <p>Using AFP, with 20 ng/mL, as threshold, about 40% of HCC occurrences would be missed, and with US alone, more than a quarter. The sensitivity was highest when the two tests were used in combination, and less than 5% of HCC occurrences would be missed with about 15% of false‐positive results. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>5 June 2020</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013346-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013346-sec-0097"></div> <h3 class="title" id="CD013346-sec-0098">Implications for practice</h3> <section id="CD013346-sec-0098"> <p>Hepatocellular carcinoma (HCC) is a frequent complication of chronic liver disease. The detection of a tumour amenable to surgical resection, thermal ablation, or liver transplantation could improve the prognosis which in the absence of indications to radical treatment is severe. Being the fourth leading cause of death from cancer worldwide, accurate tests are needed to diagnose HCC, either in a surveillance programme or in a clinical setting. In the clinical pathway for the diagnosis of HCC in people with chronic liver disease, AFP and US are the first step investigations. Both tests, in separate or in combination, can be considered as triage tests. Ideally, they should ensure a low proportion of false‐negative results because people with undetected HCC cannot receive proper treatment. False‐positive results would have less severe consequences as misclassified people would undergo unnecessary further testing with CT, MRI, or rarely biopsy. </p> <p>In surveillance programmes for HCC in high risk patients, the pooled sensitivity of alpha‐foetoprotein (AFP) measurement, with a cut‐off value of 20 mg/mL, suggests that using this test alone, a relevant number of HCC occurrences would be missed. The estimated sensitivity of ultrasound (US) is higher, but again more than a quarter of HCC occurrences would be missed. The combination of the two tests, considered positive when at least one is positive, reduces the false‐negative ratio to around 5%, sparing further testing in case of negative results. The cost of the improvement of the sensitivity is an increased number of false‐positive results from 6% to 15%<b>.</b> Moreover, our findings suggest that US sensitivity decreases for the diagnosis of potentially resectable HCC. </p> <p>In a clinical setting, where the pre‐test probability of having an HCC is expected to be higher than in surveillance programmes, both US and AFP, with a cut‐off value of 20 ng/mL, have an estimated specificity higher than 80%, AFP with a cut‐off value of 200 ng/mL, allows confirmation of the diagnosis with a specificity even around 99%. In any case, further testing is required for staging the disease and planning appropriate treatment. However, the role of these two tests is mainly as triage tests, but they individually do not ensure an adequate sensitivity. In particular, AFP is higher than 200 mg/mL only in 36% of patients with HCC. Therefore, clinicians cannot avoid further testing in case of negative results. In this context, the role of the combination of AFP and US cannot be assessed as we found only one study with pathology of explanted liver as reference standard. </p> <p>Overall, caution is needed in interpreting our review results as we found large heterogeneity which is not due to a few outliers, and despite the investigation of multiple potential factors, heterogeneity remains unexplained. Furthermore, all studies were at high risk of bias, and most of them with high concern regarding their applicability, mainly due to participant selection domain. </p> </section> <h3 class="title" id="CD013346-sec-0099">Implications for research</h3> <section id="CD013346-sec-0099"> <p>As the evidence of the accuracy of AFP, US, and especially of the combination of AFP and US is not conclusive, further studies are needed. In order to obtain more consistent and applicable results; these studies should assess the sensitivity and specificity of AFP and US in people with chronic liver disease at a definite risk for HCC, with a cross‐sectional design, evaluating either participants with positive or negative results of the index test with computed tomography (CT) or magnetic resonance imaging (MRI) as the reference standard. This reference standard, even if not absolutely accurate, should be chosen as in the clinical pathway both AFP and US tests play the role of a triage test, just before CT and MRI tests. The time interval between the index test and the reference standard should be clearly reported and should not exceed three months. The number of uninterpretable results should be reported at least for US due to their not negligible frequency. Moreover, no further study with a case‐control design can be expected to be informative. </p> <p>To explore the possible role of these tests on patient relevant outcomes, beyond their accuracy, studies with different designs are needed (<a href="./references#CD013346-bbs2-0579" title="ColliA , FraquelliM , CasazzaG , ConteD , NikolovaD , DucaP , et al. The architecture of diagnostic research: from bench to bedside--research guidelines using liver stiffness as an example. Hepatology2014;60(1):408-18.">Colli 2014</a>). Only randomised clinical trials assessing the overall mortality in different surveillance programmes including these tests in separate or in combination could properly answer this question. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013346-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013346-sec-0008"></div> <div class="table" id="CD013346-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">'Summary of findings' table: diagnostic accuracy of AFP, US, and combination of AFP and US for the diagnosis of HCC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question</b>: what is the diagnostic accuracy of alpha‐foetoprotein (AFP), abdominal ultrasound (US), or of the combination of AFP and abdominal US for the diagnosis of hepatocellular carcinoma (HCC) in adults with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting</b>: clinical setting (secondary or tertiary care setting) or surveillance programs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design</b>: prospective and retrospective cross‐sectional and case‐control studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index tests</b> </p> <p>Serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL</p> <p>Serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 200 ng/mL</p> <p>Abdominal ultrasound (US)</p> <p>Combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound (US) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition</b>: HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b>: </p> <p>the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up period of at least six months to exclude the presence of focal lesions non detected by the index test and synchronous lesions from the parenchyma surrounding the resected or biopsied area; </p> <p>typical characteristics on cross‐sectional multiphasic contrast computer tomography (CT) or magnetic resonance imaging (MRI), with a follow‐up period of at least six months in order to allow the confirmation of an initial negative result on CT or on MRI. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence ‐ Risk of bias/Applicability</b> </p> <p><b>Index test</b>: serum alpha‐foetoprotein (AFP) measurement cut‐off value 20 ng/mL </p> <p>‐ Participant selection: high/unclear risk of bias 141 studies (96%), high concern 115 studies (78%) </p> <p>‐ Index tests: high/unclear risk of bias in 73 studies (50%) high concern: no study</p> <p>‐ Reference standard: high/unclear risk of bias in 105 studies (71%) high concern 33 studies (22%) </p> <p>‐ Flow and timing: high risk of bias in 143 studies (97%)</p> <p><b>Index test</b>: serum alpha‐foetoprotein (AFP) measurement cut‐off value 200 ng/mL </p> <p>‐ Participant selection: high/unclear risk of bias 48 studies (86%), high concern 47(84%) </p> <p>‐ Index tests: high/unclear risk of bias in 54 studies (96%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 39 studies (70%) high concern 13 studies (23%) </p> <p>‐ Flow and timing: high risk of bias in 55 studies (98%)</p> <p><b>Index test</b>: abdominal ultrasound </p> <p>‐ Participant selection: high/unclear risk of bias in 23 studies (59%) high concern 22 studies (56%) </p> <p>‐ Index tests: high/unclear risk of bias in 15 studies (38%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 27 studies (69%) high concern 13 studies (33%) </p> <p>‐ Flow and timing: high risk of bias in 27 studies (TN) (69%)</p> <p><b>Index test</b>: combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound </p> <p>‐ Participant selection: high/unclear risk of bias in 2 studies (33%) high concern 2 studies (33%) </p> <p>‐ Index tests: high/unclear risk of bias in 2 studies (33%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 4 studies (67%) high concern one study (17%) </p> <p>‐ Flow and timing: high risk of bias in 6 studies (100%)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Findings</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Implications in a hypothetical cohort of 1000 people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Index test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies (participants</b>) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed prevalence of hepatocellular carcinoma (HCC)<sup>a</sup> </b> </p> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True positives</b> will receive appropriately further necessary testing with CT or MRI, or contrast enhanced ultrasound (CEUS) and possibly treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False negatives</b> will be misdiagnosed and not receive appropriate treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True negatives</b> will not appropriately undergo unnecessary further testing with CT, MRI, CEUS, biopsy. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False positives</b> will inappropriately undergo further unnecessary testing with CT, MRI, CEUS biopsy. </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AFP (cut‐off 20 ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147</p> <p>(52144)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59.8%</p> <p>(57.9% to 61.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84.4%</p> <p>(82.3% to 86.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>802</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>b</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AFP (cut‐off 200 ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56</p> <p>(20452)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36% (31% to 41%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99% (98% to 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>940</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>c</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39</p> <p>(18792)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72%</p> <p>(63% to 79%),</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94% (91% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>893</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>d</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combination of AFP (cut‐off 20 ng/mL) and US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p>(5044)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96%</p> <p>(88% to 98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85%</p> <p>(73% to 93%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>low <sup>e</sup> </p> <p>⨁⨁◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup> We chose for exemplification two values of HCC prevalence: 5% for a population at low risk (compensated advanced chronic liver disease and chronic viral hepatitis) <a href="./references#CD013346-bbs2-0607" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gatroenterology2009;136(1):138-48.">Lok 2009</a> and 30% for a population with high risk, a median of the prevalence in the included cross‐sectional studies conducted in clinical cohorts. </p> <p><sup>b</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 24% to 90% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>c</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 4% to 83% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>d</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 28%to 100% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>e</sup>Downgraded by two levels: risk of bias, indirectness. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum). </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013346-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table: direct comparison of US, and combination of AFP and US</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Review question</b>: what is the diagnostic accuracy of the combination of alpha‐foetoprotein (AFP) and abdominal ultrasound (US) compared to US for the diagnosis of hepatocellular carcinoma (HCC) in adults with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Setting</b>: clinical setting (secondary or tertiary care setting) or surveillance programs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Study design</b>: prospective and retrospective cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Index tests</b>:abdominal ultrasound; combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Target condition</b>: HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Reference standards</b>:the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up period of at least six months to exclude the presence of focal lesions non detected by the index test and synchronous lesions from the parenchyma surrounding the resected or biopsied area;typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months in order to allow the confirmation of an initial negative result on computer tomography (CT) or on magnetic resonance imaging (MRI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Limitations in the evidence</b> </p> <p><b>Risk of bias/ Applicability</b> </p> <p>‐ Participant selection: high/unclear risk of bias in 2 studies (33%)/ high concern 2 studies (33%) </p> <p>‐ Index tests: high/unclear risk of bias in 2 studies (33%)/ high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 4 studies (67%)/ high concern 1 study (17%) </p> <p>‐ Flow and timing: high risk of bias in 6 studies (100%)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Findings</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Implications in a hypothetical cohort of 1000 people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index test</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies (participants</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> <p>(95% CI)</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative sensitivity (95% CI)</b> </p> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative specificity</b> </p> <p><b>(95% CI)</b> </p> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed prevalence of hepatocellular carcinoma (HCC)<sup>a</sup> </b> </p> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True positives</b> <br/>will receive appropriately further necessary testing with CT or MRI, or contrast enhanced ultrasound (CEUS) and possibly treatment . </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False negatives</b> <br/>will be misdiagnosed and not receive appropriate treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True negatives</b> <br/>will not appropriately undergo unnecessary further testing with CT, MRI, CEUS, biopsy </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False positives</b> <br/>will inappropriately undergo further unnecessary testing with CT, MRI, CEUS biopsy. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6 (5044)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>76% (56% to 89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1.28 (1.03 to 1.539</p> <p>P = 0.014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93% (80% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.94, (0.87 to 1.01)</p> <p>P = 0.102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>883</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>low<sup>b</sup> </p> <p>⨁⨁◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>651</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combination of AFP (cut‐off 20 ng/mL) and US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96% (88% to 98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85% (73% to 82%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p><sup>a</sup> We chose for exemplification two values of HCC prevalence: 5% for a population at low risk (compensated advanced chronic liver disease and chronic viral hepatitis) <a href="./references#CD013346-bbs2-0607" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gatroenterology2009;136(1):138-48.">Lok 2009</a> and 30% for a population with high risk, a median of the prevalence in the included cross‐sectional studies conducted in clinical cohorts. </p> <p><sup>b</sup>Downgraded by two levels: risk of bias, indirectness. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum) </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013346-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013346-sec-0009"></div> <p>Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm, usually developing in the setting of chronic liver disease. It is the sixth most commonly diagnosed cancer and the fourth leading cause of death from cancer worldwide; there were 782,000 deaths due to HCC in 2018 (<a href="./references#CD013346-bbs2-0570" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). In men, HCC ranks fifth in terms of global cases of cancer and second in terms of cancer deaths (<a href="./references#CD013346-bbs2-0570" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). In Western countries, the incidence and mortality rates of HCC increased substantially between 1990 and 2015 (<a href="./references#CD013346-bbs2-0622" title="RyersonAB , EhemanCR , AltekruseSF , WardJW , JemalA , ShermanRL , et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer2016;122(9):1312-37.">Ryerson 2016</a>; <a href="./references#CD013346-bbs2-0589" title="Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncology2017;3(12):1683-91.">GBD 2017</a>). Most common risk factors include liver cirrhosis, severe liver fibrosis, hepatitis B, hepatitis C, alcohol intake, and non‐alcoholic fatty liver disease (<a href="./references#CD013346-bbs2-0635" title="YangJD , HarmsenWS , SlettedahlSW , ChaiteerakijR , EndersFT , TherneauTM , et al. Factors that affect the risk for hepatocellular carcinoma and effects of surveillance. Clinical Gastroenterology and Hepatology2011;9(7):617-23.">Yang 2011</a>), although some people may develop HCC without the presence of known risk factors (<a href="./references#CD013346-bbs2-0569" title="BraletMP , RegimbeauJM , PineauP , DuboisS , LoasG , DegosF , et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology (Baltimore, Md.)2000;32(2):200-4.">Bralet 2000</a>; <a href="./references#CD013346-bbs2-0637" title="YoungAL , AdairR , PrasadKR , ToogoodGJ , LodgeJP . Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. Journal of the American College of Surgeons2012;214(2):174-83.">Young 2012</a>). </p> <p>Clinically, HCC is frequently diagnosed in the late stages because of the absence of specific symptoms of the malignancy, other than those related to chronic liver disease. Only 20% of patients with HCC are eligible for curative treatments — such as liver resection, transplantation, or ablation — due to advanced tumour stage, liver dysfunction, or shortage of liver donors (<a href="./references#CD013346-bbs2-0580" title="DavilaJA , DuanZ , McGlynnKA , El-SeragHB . Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. Journal of Clinical Gastroenterology2012;46:71-7.">Davila 2012</a>). According to the current guidelines, HCC can only be considered as resectable and amenable to surgical radical resection if the cancer presents as either a single lesion with a maximum diameter of less than 5 cm, or up to three lesions, each with a maximum diameter of 3 cm (<a href="./references#CD013346-bbs2-0608" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334:693-9.">Mazzaferro 1996</a>; <a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>). Furthermore, curative treatment options are not feasible for most patients due to severe clinical deterioration at the moment of diagnosis, or due to the inaccuracy of the preoperative clinical evaluation and staging procedure. </p> <p>Despite the poor initial prognosis (the mortality‐to‐incidence overall ratio has been reported as 0.93; (<a href="./references#CD013346-bbs2-0570" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>)), a five‐year survival rate of more than 50% can be achieved if HCC is detected at an early stage (<a href="./references#CD013346-bbs2-0586" title="FornerA , LlovetJM , BruixJ . Hepatocellular carcinoma. Lancet2012;379(9822):1245-55.">Forner 2012</a>). According to the Barcelona Clinic Liver Cancer staging system, only patients with early‐stage HCC are eligible for curative treatment (<a href="./references#CD013346-bbs2-0604" title="LlovetJM , BruC , BruixJ . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease1999;19:329-38.">Llovet 1999</a>). Therefore, it is very important to make an accurate diagnosis of HCC as early as possible. </p> <p>Abdominal ultrasound (US) has become an acceptable imaging modality in detecting HCC because it is non‐invasive, acceptable to patients, has moderate costs, and no associated risks. A recent meta‐analysis showed a pooled sensitivity of 84% of US surveillance in detecting HCC in people without any symptoms (<a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>). However, the same publication showed a poor result for US in the detection of early‐stage HCC in people who are eligible for curative therapies, with a pooled sensitivity of only 47% (<a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>). Accordingly, detection of HCC poses a challenge. The sonographic liver tissue characteristics in people with fibrosis make it particularly difficult to detect and differentiate small neoplastic nodules from the surrounding parenchyma and from regenerative nodules. Furthermore, the performance of US can be influenced by the expertise of the operator and the quality of the equipment. </p> <p>Alpha‐foetoprotein (AFP) is a tumour marker which has been used as a diagnostic test for HCC since the 1970s, when most patients were diagnosed in the late stage and with clinical symptoms (<a href="./references#CD013346-bbs2-0597" title="KewMC . Alpha-fetoprotein. In: ReadAE , editors(s). Modern Trends in Gastroenterology. Vol. 5. London: Butterworths, 1975:91.">Kew 1975</a>). Although the test for AFP is widely available, inexpensive, and easy to perform, it has poor accuracy as a serological test for the early detection of HCC (<a href="./references#CD013346-bbs2-0632" title="TateishiR , YoshidaH , MatsuyamaY , MineN , KondoY , OmataM . Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International2008;2:17-30.">Tateishi 2008</a>). Levels of AFP increase not only in people with HCC, but also in people with active hepatitis, cirrhosis without HCC, or exacerbation of the underlying liver disease, due to pathophysiological changes of inflammation and regeneration; this means the test can have low specificity in the population at risk (<a href="./references#CD013346-bbs2-0582" title="Di BisceglieAM , SterlingRK , ChungRT , EverhartJE , DienstagJL , BonkovskyHL , et al. Serum alpha-fetoprotein levels inpatients with advanced hepatitis C: results from the HALT-C Trial. Journal of Hepatology2005;43:434–41.">Di Bisceglie 2005</a>; <a href="./references#CD013346-bbs2-0104" title="GopalP , YoppAC , WaljeeAK , ChiangJ , NehraM , KandunooriP , et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clinical Gastroenterology and Hepatology2014;12(5):870–7. ">Gopal 2014</a>). </p> <p>Surveillance programmes for early detection of HCC in high‐risk patients have been implemented in the current medical practice in most Western and Asian‐Pacific countries, despite the very low‐certainty evidence regarding the effects on mortality (<a href="./references#CD013346-bbs2-0596" title="KansagaraD , PapakJ , PashaAS , O'NeilM , FreemanM , RelevoR , et al. Screening for hepatocellular carcinoma in chronic liver disease. Annals of Internal Medicine2014;161:261-9.">Kansagara 2014</a>; <a href="./references#CD013346-bbs2-0631" title="SingalAG , PillaiA , TiroJ . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Medicine2014;11:e1001624.">Singal 2014</a>). The American Association for the Study of Liver Disease (AASLD), European Association for the Study of the Liver with European Organization for Research and Treatment of Cancer (EASL‐EORTC), and Asian Pacific Association for the Study of the Liver (APASL) recommend abdominal US as an imaging modality for surveillance of HCC every six months in people at risk. However, disagreement exists between using serum biomarker AFP as an additional test (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>). </p> <p>There are several published systematic reviews which examine the accuracy of ultrasonography and AFP in detecting HCC (<a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD013346-bbs2-0632" title="TateishiR , YoshidaH , MatsuyamaY , MineN , KondoY , OmataM . Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International2008;2:17-30.">Tateishi 2008</a>; <a href="./references#CD013346-bbs2-0630" title="SingalA , VolkML , WaljeeA , SalgiaR , HigginsP , RogersMA , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2009;30:37-47.">Singal 2009</a>; <a href="./references#CD013346-bbs2-0596" title="KansagaraD , PapakJ , PashaAS , O'NeilM , FreemanM , RelevoR , et al. Screening for hepatocellular carcinoma in chronic liver disease. Annals of Internal Medicine2014;161:261-9.">Kansagara 2014</a>; <a href="./references#CD013346-bbs2-0631" title="SingalAG , PillaiA , TiroJ . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Medicine2014;11:e1001624.">Singal 2014</a>; <a href="./references#CD013346-bbs2-0576" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinsburgA , et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>; <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>), but to our knowledge, there is no recent systematic review which compares AFP alone, US alone, and the combination of AFP and US in detecting HCC. Therefore, the aim of our review is to use Cochrane methodology to assess the diagnostic accuracy of these three modalities for the diagnosis of HCC, as well as the early stage of HCC (when the cancer may still be resectable), in people with chronic liver disease. </p> <section id="CD013346-sec-0010"> <h3 class="title" id="CD013346-sec-0010">Target condition being diagnosed</h3> <p>Hepatocellular carcinoma is the most common primary liver cancer which occurs mostly in people with chronic liver disease. The incidence of HCC increases in individuals with hepatitis B and C, alcohol use, and non‐alcoholic fatty liver disease, and in those with liver cirrhosis of various aetiologies (<a href="./references#CD013346-bbs2-0571" title="BruixJ , ShermanM . Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.)2011;53(3):1020.">Bruix 2011</a>). There is no definite threshold in the definition of lesion size, although the literature tends to classify lesions with a diameter equal to or less than 2 cm as 'small' (<a href="./references#CD013346-bbs2-0593" title="HussainSM , ZondervanPE , IJzermansJN , SchalmSW , deManRA , KrestinGP . Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics2002;22:1023–39.">Hussain 2002</a>; <a href="./references#CD013346-bbs2-0575" title="ChoiJY , LeeJM , SirlinCB . CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.">Choi 2014</a>; <a href="./references#CD013346-bbs2-0614" title="ParkHJ , ChoiBI , LeeES , ParkSB , LeeJB . How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer2017;6:189–203.">Park 2017</a>). </p> <p>In clinical practice, and according to pertinent guidelines, multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) with intravascular contrast allow for a highly accurate diagnosis of HCC, without an invasive biopsy (<a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>). The diagnosis of HCC is usually obtained on the basis of cross‐sectional CT or MRI features: focal liver lesions which show non‐rim‐like hyper enhancement in the arterial phase, subsequent non‐peripheral washout appearance, and capsule appearance (<a href="./references#CD013346-bbs2-0603" title="The American College of Radiology. CT/MRI LI-RADS v2018. www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 2018 (accessed 1 June 2020).">LI‐RADS 2018</a>). Liver histology is required only for undefined lesions during CT and MRI (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>). </p> <p>A number of staging systems for HCC have been proposed and developed; however, there is no globally applicable staging system (<a href="./references#CD013346-bbs2-0598" title="KinoshitaA , OnodaH , FushiyaN , KoikeK , NishinoH , TajiriH . Staging systems for hepatocellular carcinoma: current status and future perspectives. World Journal of Hepatology2015;7(3):406–24.">Kinoshita 2015</a>). Among different staging protocols, the Barcelona Clinic Liver Cancer (BCLC) classification system has a notable feature of treatment recommendations for each stage, based on the best treatment options currently available (<a href="./references#CD013346-bbs2-0604" title="LlovetJM , BruC , BruixJ . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease1999;19:329-38.">Llovet 1999</a>; <a href="./references#CD013346-bbs2-0605" title="LlovetJM , BurroughsA , BruixJ . Hepatocellular carcinoma. Lancet2003;362:1907-17.">Llovet 2003</a>; <a href="./references#CD013346-bbs2-0606" title="LlovetJM , Di BisceglieAM , BruixJ , KramerBS , LencioniR , ZhuAX , et al. Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute2008;100:698–711.">Llovet 2008</a>). The staging is based on four elements: tumour extension, liver functional reserve, physical status, and cancer‐related symptoms. According to the BCLC classification system, only patients with early‐stage HCC are eligible for curative treatment, such as surgical resection or percutaneous treatment. Orthotopic liver transplantation is reserved for patients with decompensated cirrhosis. </p> <p>Orthotopic liver transplantation is considered a definite curative treatment for HCC. When orthotopic liver transplantation for HCC was initially introduced in the 1980s, it was associated with poor five‐year survival rates and high recurrence rates, which led to the treatment being contraindicated for HCC (<a href="./references#CD013346-bbs2-0636" title="YokoyamaI , TodoS , IwatsukiS , StarzlTE . Liver transplantation in the treatment of primary liver cancer. Hepato-gastroenterology1990;37(2):188-93.">Yokoyama 1990</a>). In 1996, specific criteria, known as Milan criteria (<a href="./references#CD013346-bbs2-0608" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334:693-9.">Mazzaferro 1996</a>), were developed for the selection of patients for liver transplantation. With the implementation of these criteria, the overall five‐year survival rates for post‐orthotopic liver transplantation patients exceeded 70% (<a href="./references#CD013346-bbs2-0609" title="MazzaferroV , BhooriS , SpositoC , BonginiM , LangerM , MiceliR , et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence based analysis of 15 years of experience. Liver Transplantation2011;17:S44-57.">Mazzaferro 2011</a>). The criteria for patients eligible for orthotopic liver transplantation include: a single HCC lesion with a diameter equal to or less than 5 cm, or up to three HCC lesions, each with a diameter equal to or less than 3 cm; no vascular invasion; and no extrahepatic involvement (no metastasis). The same criteria are recommended for the selection of patients eligible for surgical resection. </p> <p>Along with interferon‐based treatment, a new direct‐acting antiviral (DAA) therapy was developed for people with chronic hepatitis C; these therapies therefore acted against one of the major risk factors for developing HCC (<a href="./references#CD013346-bbs2-0568" title="BourliereM , BronowickiJP , deLedinghenV , HezodeC , ZoulimF , MathurinP , et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infectious Diseases2015;15:397–404.">Bourliere 2015</a>; <a href="./references#CD013346-bbs2-0574" title="CharltonM , EversonGT , FlammSL , KumarP , LandisC , Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology2015;149:649–59.">Charlton 2015</a>; <a href="./references#CD013346-bbs2-0601" title="LeroyV , AngusP , BronowickiJP , DoreGJ , HezodeC , PiankoS , et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3 +). Hepatology (Baltimore, Md.)2016;63:1430–41.">Leroy 2016</a>). DAA therapy allowed the achievement of sustained virologic response (SVR) in more than 70% of patients, compared to less than 40% with interferon therapy (<a href="./references#CD013346-bbs2-0595" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD012143. [DOI: 10.1002/14651858.CD012143.pub3]">Jakobsen 2017</a>; <a href="./references#CD013346-bbs2-0573" title="CalvarusoV , CabibboG , CacciolaI , PettaS , MadoniaS , BelliaA , et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology2018;155(2):411-21.e4.">Calvaruso 2018</a>). However, a consensus exists that even after achieving SVR, people with chronic hepatitis C should be surveyed closely, especially those with advanced fibrosis and those who received a recent treatment for HCC in order to detect HCC at an early stage (<a href="./references#CD013346-bbs2-0572" title="ButtAS , SharifF , AbidS . Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: biologically plausible or an epiphenomenon?World Journal of Hepatology2018;10(2):267-76.">Butt 2018</a>). </p> </section> <section id="CD013346-sec-0011"> <h3 class="title" id="CD013346-sec-0011">Index test(s)</h3> <p>Abdominal US is a safe, inexpensive, non‐invasive, and real‐time diagnostic technique with relatively low costs. A transducer transforms electrical energy into sound waves (two megahertz (mHz) to eight mHz) and transmits them into the body. Simultaneously, the transducer detects the sound waves reflected by the underlying tissue. The intensity of these reflected (echo) waves is based on several properties of the tissue, such as density, depth, and properties of adjacent tissues. The echo waves are converted into electrical energy and displayed as a cross‐sectional tomography image. </p> <p>According to the Liver Reporting and Data System (LI‐RADS) for detection of HCC, there are three US categories for diagnosing suspected liver lesions: US‐1 (negative), US‐2 (subthreshold), and US‐3 (positive). Since US is an operator‐dependent imaging modality and limitations due to patient characteristics can occur, an US visualisation score is added: A (no or minimal limitations); B (moderate limitations); and C (severe limitations). A negative observation is reported when no liver lesions have been detected or the detected lesions are definitely benign. Subthreshold lesions of less than 10 mm are noted only when no definitely benign features have been observed. A positive observation is reported when a lesion of more than 10 mm with no definitely benign features is observed, or a new venous thrombus has been detected (<a href="./references#CD013346-bbs2-0603" title="The American College of Radiology. CT/MRI LI-RADS v2018. www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 2018 (accessed 1 June 2020).">LI‐RADS 2018</a>; <a href="./references#CD013346-bbs2-0619" title="RodgersSK , FetzerDT , GabrielH , SeowJH , ChoiHH , MaturenKE , et al. Role of US LI-RADS in the LI-RADS algorithm. Radiographics2019;39:690-708.">Rodgers 2019</a>). </p> <p>Alpha‐foetoprotein (AFP) is a glycoprotein of 591 amino acids and a carbohydrate moiety which is assessed in serum by enzyme immunoassays (<a href="./references#CD013346-bbs2-0616" title="PucciP , SicilianoR , MalorniA , MarinoG , TecceMF , CeccariniC , et al. Human alpha-fetoprotein primary structure: a mass spectrometric study. Biochemistry1991;30(20):5061-6.">Pucci 1991</a>). In presence of HCC, high serum values of AFP are reported with variable accuracy (<a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD013346-bbs2-0632" title="TateishiR , YoshidaH , MatsuyamaY , MineN , KondoY , OmataM . Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International2008;2:17-30.">Tateishi 2008</a>; <a href="./references#CD013346-bbs2-0630" title="SingalA , VolkML , WaljeeA , SalgiaR , HigginsP , RogersMA , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2009;30:37-47.">Singal 2009</a>; <a href="./references#CD013346-bbs2-0596" title="KansagaraD , PapakJ , PashaAS , O'NeilM , FreemanM , RelevoR , et al. Screening for hepatocellular carcinoma in chronic liver disease. Annals of Internal Medicine2014;161:261-9.">Kansagara 2014</a>; <a href="./references#CD013346-bbs2-0631" title="SingalAG , PillaiA , TiroJ . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Medicine2014;11:e1001624.">Singal 2014</a>; <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018)</a>. </p> </section> <section id="CD013346-sec-0012"> <h3 class="title" id="CD013346-sec-0012">Clinical pathway</h3> <p>For people with chronic liver disease, a surveillance programme is usually recommended. There are minimal variations among the surveillance programmes of the different scientific societies (<a href="#CD013346-tbl-0003">Table 1</a>). </p> <div class="table" id="CD013346-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Guideline recommendations for surveillance for hepatocellular carcinoma</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>GUIDELINE</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>INDICATION TO SURVEILANCE</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>TEST</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>INTERVAL</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Association for the Study of Liver Disease (AASLD; (<a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound alone or plus AFP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Association for the Study of the Liver with European Organization for Research and Treatment of Cancer (EASL‐EORTC; (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis in Child Pugh stages A and B; cirrhosis in Child C stage awaiting liver transplantation; non‐cirrhotic hepatitis B virus (HBV) carriers with active hepatitis or family history of HCC; non‐cirrhotic chronic hepatitis C with advanced liver fibrosis stage 3 (F3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> <p>3 to 4 months: people with a nodule less than 1 cm or after resection or loco‐regional therapies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian Pacific Association for the Study of the Liver (APASL; (<a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis and chronic HBV infection at risk of HCC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound with serum AFP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AFP:</b> alpha‐foetoprotein; <b>HCC:</b> hepatocellular carcinoma </p> </div> </div> <section id="CD013346-sec-0013"> <h4 class="title">American Association for the Study of Liver Disease (AASLD) guidelines</h4> <p>According to the AASLD guidelines, to increase overall survival, only adults with cirrhosis who are considered at risk of developing HCC need surveillance. It is suggested that surveillance be performed using abdominal US, with or without AFP, every six months. However, it is not possible to determine which type of surveillance test (ultrasound alone or ultrasound plus AFP) would lead to a greater improvement in survival. Surveillance is not suggested for those with Child‐Pugh class C cirrhosis, unless they are on the liver transplant waiting list, because of low anticipated survival (<a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>). </p> </section> <section id="CD013346-sec-0014"> <h4 class="title">European Association for the Study of the Liver with European Organization for Research and Treatment of Cancer (EASL‐EORTC) guidelines </h4> <p>According to the EASL‐EORTC guidelines, people at risk of developing HCC for which surveillance should be performed include: people with Child‐Pugh stage A or stage B cirrhosis, people with Child‐Pugh stage C cirrhosis awaiting liver transplantation, non‐cirrhotic hepatitis B virus carriers with active hepatitis or family history of HCC, and people with chronic hepatitis C in the absence of cirrhosis but with advanced liver fibrosis stage 3 (F3). People on liver transplant waiting lists should be screened for HCC in order to detect and manage tumour progression. Surveillance should be performed using abdominal US every six months. A three‐ to four‐month interval is recommended in people where a nodule of less than 1 cm has been detected, and in the follow‐up strategy, after resection or loco‐regional therapies. Serum biomarkers such as AFP, AFP‐L3 (third electrophoretic form of lentil lectin‐reactive AFP), and des‐gamma‐carboxy prothrombin are suboptimal for routine clinical practice, and therefore, not recommended for screening (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>). </p> </section> <section id="CD013346-sec-0015"> <h4 class="title">Asian Pacific Association for the Study of the Liver (APASL) guidelines</h4> <p>According to the APASL guidelines, the following people are at risk of HCC development and therefore are eligible for HCC screening: those with cirrhosis, those who have chronic hepatitis B virus infection with cirrhosis, and those who have chronic hepatitis B virus infection in the absence of cirrhosis. The optimal surveillance strategy includes abdominal US with serum AFP measurement every six months. Measurement of AFP alone is not recommended for routine surveillance of people with HCC (<a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>). </p> </section> <section id="CD013346-sec-0016"> <h4 class="title">Outside surveillance programmes</h4> <p>Ultrasound and AFP are usually performed in people with clinically suspected HCC, or liver cirrhosis, or both, or at the moment of decompensation of chronic liver disease, or all these factors together. </p> </section> <section id="CD013346-sec-0017"> <h4 class="title">Prior test(s)</h4> <p>The diagnosis of liver cirrhosis is usually based on clinical judgement derived from history, laboratory testing, physical examination, imaging, liver stiffness measurement, liver histology, or a combination of these. Due to the accuracy of non‐invasive tests, liver histology is reserved to only a minority of patients with unclear diagnosis, and a non‐invasive diagnosis of advanced chronic liver disease is considered equivalent to a histological diagnosis of cirrhosis (<a href="./references#CD013346-bbs2-0581" title="deFranchisR . Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. Journal of Hepatology2015;63:743–52.">de Franchis 2015</a>). No test is recommended by the above guidelines, prior to a surveillance programme for HCC detection. </p> </section> <section id="CD013346-sec-0018"> <h4 class="title">Role of index test(s)</h4> <p>Abdominal US and AFP (independently, or in combination, or in sequence) are used as triage tests to exclude the presence of focal liver lesions suspected of being HCC. Further alternative testing is required to confirm the diagnosis as well as staging. </p> </section> <section id="CD013346-sec-0019"> <h4 class="title">Alternative test(s)</h4> <p>Contrast‐enhanced ultrasound (CEUS) is an advanced form of US examination in which images are acquired using intravenously injected microbubble contrast agent with optimised technology required for contrast visualisation. The CEUS exam consists of a 'bolus' administration of contrast media through a superficial peripheral vein. The sequence of blood entering the liver is first arterial (10 seconds to 40 seconds), then portal (40 seconds to 120 seconds after injection), and then late venous (more than 120 seconds). This vascular discrimination, similar to that obtained by contrast CT or MRI, allows for the collection of information regarding the circulatory system of a tumour (e.g. types of feeding vessels, tumour circulatory volume). Positivity criteria for HCC are based on arterial hyper enhancement and subsequent washout appearance. The advantages of US agent over CT and MRI agents include no adverse reactions, possible multiple injections of contrast in the same examination, safety, practicality, no risk of nephrotoxicity, and no ionising radiation (<a href="./references#CD013346-bbs2-0577" title="ChungYE , KimKW . Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography2015;34(1):3-18.">Chung 2015</a>). </p> <p>Contrast‐enhanced multiphasic multi detector CT and contrast‐enhanced MRI have been established as relevant non‐invasive modalities for detection and evaluation of liver lesions (<a href="./references#CD013346-bbs2-0600" title="LeeJM , YoonJH , KimKW . Diagnosis of hepatocellular carcinoma: newer radiological tools. Seminars in Oncology2012;39:399-409.">Lee 2012</a>; <a href="./references#CD013346-bbs2-0612" title="O'NeillEK , CogleyJR , MillerFH . The ins and outs of liver imaging. Clinics in Liver Disease2015;19:99-121.">O'Neill 2015</a>). The ability to detect HCC rests on characterising the enhancement patterns in arterial, portal venous and subsequent phases relative to the surrounding liver tissue. The differences in blood flow and extracellular volume between HCC and normal liver tissue lead to main radiological hallmarks such as non‐rim‐like arterial phase hyper enhancement and subsequent non‐peripheral washout with enhancing capsule in later phases (<a href="./references#CD013346-bbs2-0592" title="HennedigeT , VenkateshSK . Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging2012;12(3):530-47.">Hennedige 2012</a>; <a href="./references#CD013346-bbs2-0575" title="ChoiJY , LeeJM , SirlinCB . CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.">Choi 2014</a>; <a href="./references#CD013346-bbs2-0628" title="ShahS , ShuklaA , PaunipagarB . Radiological features of hepatocellular carcinoma. Journal of Clinical and Experimental Hepatology2014;4:63-6.">Shah 2014</a>; <a href="./references#CD013346-bbs2-0603" title="The American College of Radiology. CT/MRI LI-RADS v2018. www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 2018 (accessed 1 June 2020).">LI‐RADS 2018</a>). CT is a commonly used modality for diagnosing HCC due to its short acquisition time and high spatial resolution. However, MRI offers several beneficial features such as absence of X‐ray radiation and combination of various sequences (multiphasic T1‐ and T2‐weighted sequences, diffusion‐weighted imaging, and apparent diffusion coefficient) in combination with the use of extracellular or hepatocellular gadolinium‐based contrast agent, or both (<a href="./references#CD013346-bbs2-0566" title="Arif-TiwariH , KalbB , ChundruS , SharmaP , CostelloJ , GuessnerRW , et al. MRI of hepatocellular carcinoma: an update of current practices. Diagnostic and Interventional Radiology2014;20:209-21.">Arif‐Tiwari 2014</a>; <a href="./references#CD013346-bbs2-0618" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology (Baltimore, Md.)2018;67(1):401-21.">Roberts 2018</a>). </p> <p>Apart from AFP, there are other potential serological tumour biomarkers for the detection of HCC. Des‐gamma‐carboxyprothrombin, also known as prothrombin induced by vitamin K absence‐II (PIVKA‐II), is an abnormal prothrombin protein that is increased in the serum of people with HCC. It is recognised as a specific marker for the detection and prognosis of HCC (<a href="./references#CD013346-bbs2-0594" title="ImamuraH , MatsuyamaY , MiyagawaY , IshidaK , ShimadaR , MiyagawaS , et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. British Journal of Surgery1999;89:1032–8.">Imamura 1999</a>; <a href="./references#CD013346-bbs2-0599" title="KoikeY , ShiratoriY , SatoS , ObiS , TerataniT , ImamuraM , et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer2001;91:561–9.">Koike 2001</a>), although contrary data exist on the benefit of using PIVKA‐II over AFP (<a href="./references#CD013346-bbs2-0197" title="NakamuraS , NousoK , SakaguchiK , ItoYM , OhashiY , KobayashiY , et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. American Journal of Gastroenterology2006;101(9):2038-43. ">Nakamura 2006</a>; <a href="./references#CD013346-bbs2-0602" title="LiC , ZhangZ , ZhangP , LiuJ . Diagnostic accuracy of desgamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatology Research2014;44:E11–25.">Li 2014</a>). AFP‐L3 can differentiate an increase in AFP due to HCC from that in people with benign liver disease, and from a potential biomarker for early HCC detection (<a href="./references#CD013346-bbs2-0142" title="KumadaT , ToyodaH , TadaT , KiriyamaS , TanikawaM , HisanagaY , et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. Journal of Gastroenterology2014;49(3):555-63. ">Kumada 2014</a>). Glypican‐3 (GPC3) is considered to be a promising biomarker for early detection of HCC and a potential epitope for HCC‐targeted therapies (<a href="./references#CD013346-bbs2-0638" title="ZhouF , ShangW , YuX , TianJ . Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Medicinal Research Reviews2018;38(2):741-67.">Zhou 2018</a>). Other biomarkers include Golgi protein 73, osteopontin, circulating free DNA, and microRNAs. However, none of these have been introduced in daily practice (<a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>). </p> </section> </section> <section id="CD013346-sec-0020"> <h3 class="title" id="CD013346-sec-0020">Rationale</h3> <p>Hepatocellular carcinoma is currently detected by liver ultrasound in people with chronic liver disease with normal or high AFP levels during surveillance programmes. Following ultrasound, the diagnosis is usually confirmed by high levels of AFP or by using contrast‐enhanced ultrasound (CEUS) (or both), CT, or MRI. The diagnosis in people who are not in a surveillance programme is usually obtained at decompensation of chronic liver disease (i.e. detection of oesophageal varices, gastrointestinal haemorrhage, or ascites), or during the diagnosis of previously unrecognised chronic liver disease. In such patients, liver ultrasound or AFP (or both) are also the first test(s) of choice and, if positive, further testing is required with CEUS, CT, or MRI. </p> <p>There is no clear evidence on the benefit of surveillance programmes in terms of overall survival: the conflicting results could be a consequence of inaccurate detection, ineffective treatment, or both. Assessing the diagnostic accuracy of abdominal US and AFP serum concentration may clarify whether the absence of benefit in surveillance programs might be related to under‐diagnosis. Furthermore, an assessment of the accuracy of these two tests for diagnosing HCC is needed for either ruling out, diagnosing, or supporting further testing in people with chronic liver disease who are not included in surveillance programs. </p> <p>People with previous diagnoses of, and who had previous treatments for, HCC make up a distinct group. The diagnostic accuracy for the recurrence of HCC after surgical or any other type of treatment is not the focus of this review. </p> <p>This review represents the first part of a planned overall evaluation of diagnostic performances of the most commonly used modalities for diagnosing HCC in people with chronic liver disease. The present systematic review will assess the diagnostic accuracy of ultrasound and AFP serum concentration for the diagnosis of HCC. Another systematic review will focus on the diagnostic accuracy of CEUS in characterising suspected lesions as HCC as a second‐line diagnostic modality (<a href="./references#CD013346-bbs2-0588" title="FraquelliM , NadarevicT , GiljacaV , ColliA , MileticD , ŠtimacD , et al. Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD013483. [DOI: 10.1002/14651858.CD013483]">Fraquelli 2019</a>), and a third systematic review will focus on the assessment of CT as another second‐ or third‐line imaging modality (if CEUS was used as second‐line test) in assessing focal liver lesions detected on ultrasound (<a href="./references#CD013346-bbs2-0610" title="NadarevicT , GiljacaV , ColliA , FraquelliM , CasazzaG , MileticD , et al. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD013362. [DOI: 10.1002/14651858.CD013362]">Nadarevic 2019</a>). A review assessing the accuracy of MRI for diagnosing HCC is also in progress (<a href="./references#CD013346-bbs2-0611" title="NadarevicT , ColliA , GiljacaV , FraquelliM , CasazzaG , ManzottiC , et al. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in people with chronic liver disease [Protocol]. Cochrane Database of Systematic Reviews 2020 (to be published).">Nadarevic 2020</a>). We are planning to produce an overview of the systematic reviews that assess abdominal US and AFP, CEUS, CT, and MRI for the diagnosis of HCC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013346-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013346-sec-0021"></div> <p>To assess the diagnostic accuracy of abdominal ultrasound (US) and alpha‐foetoprotein (AFP), alone or in combination, for the diagnosis of hepatocellular carcinoma (HCC) of any size and at any stage in adults with chronic liver disease, either in a surveillance programme or in a clinical setting. </p> <section id="CD013346-sec-0022"> <h3 class="title" id="CD013346-sec-0022">Secondary objectives</h3> <p> <ul id="CD013346-list-0001"> <li> <p>To assess the diagnostic accuracy of abdominal US and AFP, alone or in combination, for the diagnosis of resectable HCC in people with chronic liver disease, either in a surveillance programme or in a clinical setting. The definition of resectable HCC is a neoplasm amenable to surgical radical resection according to the current guidelines (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>), that is, a single lesion with a maximum diameter of less than 5 cm, or fewer than three lesions with a maximum diameter of 3 cm. </p> </li> <li> <p>To compare the diagnostic accuracy of individual tests versus the combination of both tests. </p> </li> <li> <p>To investigate the following predefined sources of heterogeneity:</p> <ul id="CD013346-list-0002"> <li> <p>study design (prospective compared to retrospective; case‐control studies compared to cross‐sectional cohort studies); </p> </li> <li> <p>study date (studies published before the year 2000 compared to studies published after the year 2000, due to advancements in technology and changes in diagnostic criteria); </p> </li> <li> <p>inclusion of participants without cirrhosis (studies including more than 10% participants without cirrhosis compared to studies including less than 10% participants without cirrhosis); </p> </li> <li> <p>study location (population differences): studies conducted in North and South America compared to Europe compared to Asia and Africa; </p> </li> <li> <p>prevalence of the target condition (studies with HCC prevalence more than 10% compared to studies with HCC prevalence less than 10%); </p> </li> <li> <p>participant selection (participants recruited from planned surveillance programs compared to clinical cohorts); </p> </li> <li> <p>different HCC stage (studies with more than 20% of participants with resectable HCC compared to studies with less than 20% of participants with resectable HCC); </p> </li> <li> <p>different reference standard (histology of the explanted liver compared to liver biopsy compared to another reference standard); </p> </li> <li> <p>different liver cirrhosis aetiology: studies with more than 80% participants with viral (hepatitis C or hepatitis B) chronic liver disease compared to studies with less than 80% of participants with viral chronic hepatitis; </p> </li> <li> <p>different severity of the underlying chronic liver disease: studies with more than 50% of participants with MELD (model for end‐stage liver disease) score less than 15 or with Child Pugh score A compared to studies with less than 50% of participants with MELD less than 15 or Child Pugh score A. </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013346-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013346-sec-0023"></div> <section id="CD013346-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013346-sec-0025"> <h4 class="title">Types of studies</h4> <p>We aimed to include studies, irrespective of publication status and language, that have evaluated the diagnostic accuracy of abdominal ultrasound (US) and alpha‐foetoprotein (AFP), independently or in combination, for the diagnosis of: hepatocellular carcinoma (HCC) in people with chronic liver disease. These studies should have used one of the acceptable reference standards (see below <a href="#CD013346-sec-0031">Reference standards</a>). </p> <p>We considered for inclusion studies of cross‐sectional design including participants with clinical suspicion of HCC or cohort studies including high‐risk participants in a surveillance programme, as well as studies with a case‐control design that compared people with known HCC to a matched control (participants with chronic liver disease without evidence of HCC). We excluded studies that analysed data only per lesion, that is, those that considered the number of lesions rather than participants, unless participant data were made available by study authors. </p> </section> <section id="CD013346-sec-0026"> <h4 class="title">Participants</h4> <section id="CD013346-sec-0027"> <h5 class="title">Eligibility criteria</h5> <p>We included study participants aged 18 years and older, of any sex, who are diagnosed with a chronic liver disease, irrespective of the severity and duration of the disease. Study participants should have been treatment‐naive for HCC when enrolled in the respective study. </p> </section> <section id="CD013346-sec-0028"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies which had included participants treated for HCC unless they represented less than 5% of all the included participants, or if data were presented in such a way as to allow this group of participants to be isolated from the remaining included participants. </p> </section> </section> <section id="CD013346-sec-0029"> <h4 class="title">Index tests</h4> <p>We included abdominal US alone, AFP alone, and a combination of abdominal US and AFP for the detection of HCC in adults with chronic liver disease. For AFP, different cut‐off values were used, ranging from 7 mg/mL to 400 mg/mL. For ultrasound (US), positive criteria include the minimum diameter of a detectable lesion and exclusion of benign criteria. </p> </section> <section id="CD013346-sec-0030"> <h4 class="title">Target conditions</h4> <p> <ul id="CD013346-list-0003"> <li> <p>Hepatocellular carcinoma of any size and at any stage.</p> </li> <li> <p>Resectable hepatocellular carcinoma (see <a href="#CD013346-sec-0022">Secondary objectives</a>). </p> </li> </ul> </p> </section> <section id="CD013346-sec-0031"> <h4 class="title">Reference standards</h4> <p>We accepted as a reference standard for the diagnosis of HCC one of the following.</p> <p> <ul id="CD013346-list-0004"> <li> <p>The pathology of the explanted liver in case of transplantation.</p> </li> <li> <p>The histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months to exclude the presence of focal lesions not detected by the index test and synchronous lesions from the parenchyma surrounding the resected or biopsied area. </p> </li> <li> <p>Typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months in order to allow the confirmation of an initial negative result on CT or on MRI. </p> </li> </ul> </p> <p>We acknowledge that all these reference standards, even if commonly used in clinical practice, are not perfect. The pathology of the explanted liver is possible only in the case when all the included patients undergo liver transplantation; therefore, the setting does not correspond to the clinical question as only people with advanced and decompensated liver disease are candidates for orthotopic liver transplantation. In the case of histology of resected focal lesion, histology of biopsied liver lesions, CT or MRI examination, the negative result can be confirmed only with an adequate follow‐up period. This would introduce an unavoidable differential verification bias. In addition, CT and MRI cannot be considered completely accurate. </p> </section> </section> <section id="CD013346-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013346-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group (CHBG) Controlled Trials Register and the Cochrane Hepato‐Biliary Group Diagnostic‐Test‐Accuracy Studies Register (both maintained and searched internally by the CHBG Information Specialist via the Cochrane Register of Studies Web; June 2020), the Cochrane Library (2020, Issue 6), MEDLINE Ovid (1946 to June 2020), Embase Ovid (1974 to June 2020), LILACS (Bireme; 1982 to June 2020), Science Citation Index Expanded (Web of Science; 1900 to June 2020), and Conference Proceedings Citation Index – Science (Web of Science; 1990 to June 2020; (<a href="./references#CD013346-bbs2-0620" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591–603.">Royle 2003</a>)). <a href="./appendices#CD013346-sec-0103">Appendix 1</a> gives the search strategies with the time spans of the searches. </p> <p>We applied no language or document type restrictions.</p> </section> <section id="CD013346-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify additional references by manually searching articles retrieved from digital databases and relevant review articles. We sought information on unpublished studies by contacting experts in the field. In addition, we handsearched abstract books from meetings of the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and Asia‐Paciifc Association for the study of the Liver (APASL), held over the past 10 years. We also searched for other kinds of grey literature in the System for Information on Grey Literature in Europe “OpenGrey” (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>). </p> </section> </section> <section id="CD013346-sec-0035"> <h3 class="title" id="CD013346-sec-0035">Data collection and analysis</h3> <p>We followed available guidance as provided in the <i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD013346-bbs2-0583" title="DeeksJJ , BossuytPM , GatsonisC , editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org.">DTA Handbook 2013</a>). </p> <section id="CD013346-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AC and MF) independently scrutinised half of the titles and abstracts identified by electronic literature searching to identify potentially eligible studies, and two other review authors (TN and VG) independently scrutinised the other half. We recorded any citation, identified by one of the four review authors, as potentially eligible for full‐text review. Then, two review authors (AC and TN) independently reviewed publications for eligibility. To determine eligibility, we assessed each publication to determine whether participants met the inclusion criteria detailed above. We included abstracts only if they provided sufficient data for analysis. We resolved disagreements by consensus. </p> </section> <section id="CD013346-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>We developed a standardised data extraction form and piloted the form on nine of the included studies. Based on the pilot, we finalised the form.<br/>Then, two review authors (AC and TN) completed the data extraction form for each included study. Each review author independently retrieved study data. In cases of disagreement, we reached consensus through discussion with a third review author (GC). </p> <p>We retrieved the following data.</p> <p> <ul id="CD013346-list-0005"> <li> <p>General information: title, journal, year, publication status, and study design (prospective versus retrospective), surveillance program or clinical cohorts. </p> </li> <li> <p>Sample size: number of participants meeting the criteria and total number of participants screened. </p> </li> <li> <p>Baseline characteristics: baseline diagnosis, age, sex, and presence of cirrhosis and mean diameter of HCC. </p> </li> <li> <p>Index tests with predefined positivity criteria and when appropriate all cut‐off values.</p> </li> <li> <p>Target condition.</p> </li> <li> <p>Order of tests.</p> </li> <li> <p>Time between tests.</p> </li> <li> <p>Reference standard tests.</p> </li> <li> <p>Numbers of true‐positive, true‐negative, false‐positive, false‐negative, and uninterpretable index test results. We extracted these data for each presented cut‐off value and for either HCC of any size, stage, and resectable HCC. </p> </li> </ul> </p> <p>We summarised the data from each study in 2 × 2 tables (true positive, false positive, false negative, true negative), according to the index tests considered, and we entered the data into Review Manager 5.4 software (<a href="./references#CD013346-bbs2-0617" title="The Cochrane CollaborationReview Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <section id="CD013346-sec-0038"> <h5 class="title">Missing data</h5> <p>We contacted primary authors by email to request missing data: number of AFP false‐positive results (<a href="./references#CD013346-bbs2-0356" title="BaigJA , AlamJM , MahmoodSR , BaigM , ShaheenR , SultanaI , et al. Hepatocellular carcinoma (HCC) and diagnostic significance of A-fetoprotein (AFP). Journal of Ayub Medical College, Abbottabad2009;21(1):72-5. ">Baig 2009</a>; <a href="./references#CD013346-bbs2-0374" title="ChenY , ZhoubY , QiucS , WangK , LiuaS , PengXX , et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Letters2010;289(1):32-9. ">Chen 2010</a>; <a href="./references#CD013346-bbs2-0347" title="AbdelgawadIA , MossallamGI , RadwanNH , ElzawahryHM , ElhifnawyNM . Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?Asian Pacific Journal of Cancer Prevention2013;14(12):7345-9. ">Abdelgawad 2013</a>; <a href="./references#CD013346-bbs2-0397" title="EI-EmshatyHM , GadelhakSA , AbdelazizMM , AbbasAT , GadelhakNA . Serum P53 Abs in HCC patients with viral hepatitis - type C. Hepato-gastroenterology2014;134:1688-95. ">El‐Emshaty 2014</a>; <a href="./references#CD013346-bbs2-0383" title="DenglerM , StauferK , HuberH , StauberR , BantelH , WeissKH , et al. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget2017;8(28):46234-48. ">Dengler 2017</a>), and results of per patients analyses as only per lesions were reported in <a href="./references#CD013346-bbs2-0476" title="LimJH , KimSH , LeeWJ , ChoiD , KimSH , LimHK . Ultrasonographic detection of hepatocellular carcinoma: correlation of preoperative ultrasonography and resected liver pathology. Clinical Radiology2006;61:191-7. ">Lim 2006</a>. We received no reply and sent a second email after two weeks. No reply was received; therefore, we excluded the above‐mentioned studies. </p> </section> </section> <section id="CD013346-sec-0039"> <h4 class="title">Assessment of methodological quality</h4> <p>Two review authors (AC and TN) independently assessed the risk of bias of included studies and applicability of their results using QUADAS‐2 (revised tool for quality assessment of diagnostic accuracy studies; (<a href="./references#CD013346-bbs2-0634" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529-36.">Whiting 2011</a>)). In cases of disagreement, we reached consensus through discussion. We addressed aspects of study quality involving the participant spectrum, index tests, target conditions, reference standards, and flow and timing. For studies that assessed ultrasound as the index test, the visualisation of the liver can often be sub optimal due to patient characteristics; therefore, lack of reporting or exclusion of uninterpretable results from analyses could overestimate the accuracy of ultrasound. We considered the study to be at high risk of bias if uninterpretable results were excluded from the analysis. We classified a study at high risk of bias if at least one of the domains of QUADAS‐2 was judged as being at high or unclear risk of bias (<a href="./appendices#CD013346-sec-0104">Appendix 2</a>). </p> </section> <section id="CD013346-sec-0040"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We provided a description of the included studies by calculating median values and interquartile ranges (IQR) across studies for some characteristics of our interest, defined at study level. In particular, we considered HCC mean diameter and the prevalence of participants with the following characteristics: HCC, Child‐Pugh class A, liver cirrhosis, viral aetiology of cirrhosis, and resectable HCC. </p> <p>We carried out statistical analyses according to recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD013346-bbs2-0583" title="DeeksJJ , BossuytPM , GatsonisC , editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org.">DTA Handbook 2013</a>). We designed 2 × 2 tables (see <a href="#CD013346-sec-0037">Data extraction and management</a>) for each primary study for the two index tests and for their combination. We planned the following strategy of analyses. </p> <section id="CD013346-sec-0041"> <h5 class="title">Alpha‐foetoprotein</h5> <p>Alpha‐foetoprotein (AFP) was considered positive when higher than a defined cut‐off (threshold) value was noted (<a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD013346-bbs2-0175" title="MarreroJA , FengZ , WangY , NguyenMH , BefelerAS , RobertsLR , et al. Alpha-fetoprotein, des-gamma carboxyprothrombin,and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology2009;137:110-8. ">Marrero 2009</a>; <a href="./references#CD013346-bbs2-0165" title="LokAS , SterlingRK , EverhartJE , WrightEC , HoefsJC , Di BisceglieAM , et al, HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology2010;138:493-502. ">Lok 2010</a>). Firstly, we performed a graphical descriptive analysis of the included studies. We presented forest plots (sensitivity and specificity separately, with their 95% confidence intervals (CIs)), and we provided a graphical representation of the studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). Secondly, we performed a meta‐analysis. In the case that primary studies reported accuracy estimates of AFP using different cut‐off values, we used the hierarchical summary ROC model (HSROC) in order to pool data (sensitivities and specificities) and to estimate a summary ROC (SROC) curve (<a href="./references#CD013346-bbs2-0621" title="RutterCM , GatsonisCA . A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine2001;20(19):2865-84.">Rutter 2001</a>). When considering studies with a common cut‐off value, we used the bivariate model, and we provided estimates of summary sensitivity and specificity. We used the pooled estimates obtained from the fitted models to calculate summary estimates of positive and negative likelihood ratios (LR+ and LR‐, respectively). For primary studies reporting accuracy results for more than one cut‐off value, we reported sensitivities and specificities for all cut‐off values, but we used a single cut‐off value for each study in HSROC or bivariate analysis. The most common cut‐off values were expected to be 10, 20, 200, or 400 nanograms per millilitre (ng/mL). </p> </section> <section id="CD013346-sec-0042"> <h5 class="title">Abdominal ultrasound</h5> <p>Abdominal ultrasound (US) was considered positive when a lesion of more than 10 mm with no definitely benign features was observed, or a new venous thrombus was detected according to defined criteria (<a href="./references#CD013346-bbs2-0603" title="The American College of Radiology. CT/MRI LI-RADS v2018. www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 2018 (accessed 1 June 2020).">LI‐RADS 2018</a>). Subthreshold lesions of less than 10 mm were noted only when no definitely benign features were observed (<a href="./references#CD013346-bbs2-0603" title="The American College of Radiology. CT/MRI LI-RADS v2018. www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 2018 (accessed 1 June 2020).">LI‐RADS 2018</a>). Firstly, we performed a graphical descriptive analysis of the included studies. We presented forest plots (sensitivity and specificity separately, with their 95% CIs), and we provided a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). Secondly, we performed a meta‐analysis using the bivariate model, and we provided estimates of summary sensitivity and specificity. We used the pooled estimates obtained from the fitted models to calculate summary estimates of positive and negative likelihood ratios (LR+ and LR‐, respectively). </p> </section> <section id="CD013346-sec-0043"> <h5 class="title">Uninterpretable index test results</h5> <p>In case of uninterpretable index test results (especially relevant for US), we performed a further analysis according to the intention‐to‐diagnose (ITD) principle (<a href="./references#CD013346-bbs2-0623" title="SchuetzGM , SchlattmannP , DeweyM . Use of 3x2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: meta-analytical evaluation of coronary CT angiography studies. BMJ (Clinical Research Ed.)2012;345:e6717.">Schuetz 2012</a>). We classified participants with uninterpretable results as false‐positive if they had a negative reference standard, or false‐negative result on a positive reference standard. </p> </section> <section id="CD013346-sec-0044"> <h5 class="title">Combination of abdominal ultrasound and alpha‐foetoprotein</h5> <p>The index test obtained by the combination of US and AFP tests is considered positive when at least one of the two tests is positive. Firstly, we performed a graphical descriptive analysis of the included studies. We presented forest plot results (sensitivity and specificity separately, with their 95% CIs), and we provided a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). Secondly, we performed a meta‐analysis. In the case that primary studies reported accuracy estimates of the combination of tests using different cut‐off values for AFP, we used the hierarchical summary ROC model (HSROC) to pool data (sensitivities and specificities) and to estimate a summary ROC (SROC) curve (<a href="./references#CD013346-bbs2-0621" title="RutterCM , GatsonisCA . A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine2001;20(19):2865-84.">Rutter 2001</a>). When considering studies with a common cut‐off value, we used the bivariate model and provided estimates of summary sensitivity and specificity. We used the pooled estimates obtained from the fitted models to calculate summary estimates of positive and negative likelihood ratios (LR+ and LR). For primary studies reporting accuracy results for more than one cut‐off value, we reported sensitivities and specificities for all cut‐off values, but we used a single cut‐off value for each study in HSROC or bivariate analysis. </p> </section> <section id="CD013346-sec-0045"> <h5 class="title">Comparisons</h5> <p>The combination of the two tests, US and AFP, was considered positive when at least one of the two tests was positive. We made pair‐wise comparisons between individual tests, and between individual tests and the index test obtained by the combination of the two tests when both tests are used, by adding a covariate for the index test to the bivariate model. We assessed the significance of differences in test accuracy by using the log‐likelihood ratio test for comparison of models with and without the index test covariate term. We included separate variance terms for sensitivity and specificity in the bivariate model for the two tests in comparison. We performed both indirect and direct comparisons when sufficient data were available. We calculated relative sensitivity (i.e. ratio between the sensitivities of the two index tests) and relative specificity (i.e. ratio between the two specificities). </p> <p>We considered two‐sided P values less than 0.05, as statistically significant. We performed all statistical analyses using SAS statistical software, release 9.4 (SAS Institute Inc., Cary, NC, USA) and macro METADAS (<a href="./references#CD013346-bbs2-0583" title="DeeksJJ , BossuytPM , GatsonisC , editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org.">DTA Handbook 2013</a>). </p> </section> </section> <section id="CD013346-sec-0046"> <h4 class="title">Investigations of heterogeneity</h4> <p>We investigated the effects of the following predefined sources of heterogeneity.</p> <p> <ul id="CD013346-list-0006"> <li> <p>Study design (case‐control compared to cross‐sectional studies, prospective compared to retrospective). </p> </li> <li> <p>Study date (studies before compared to after the year 2000 due to advancements in technology and change in diagnostic criteria). </p> </li> <li> <p>Inclusion of participants without cirrhosis (studies including more than 10% participants without cirrhosis compared to studies including less than 10% participants without cirrhosis). </p> </li> <li> <p>Study location (population differences): studies conducted in the USA compared to Europe compared to Asia and Africa. </p> </li> <li> <p>Prevalence of the target condition (studies with HCC prevalence of more than 10% compared to studies with HCC prevalence of less than 10%). </p> </li> <li> <p>Participant selection (participants recruited from planned surveillance programs compared to clinical cohorts). </p> </li> <li> <p>Different HCC stage (studies with more than 20% of participants with resectable HCC compared to studies with less than 20% of participants with resectable HCC). </p> </li> <li> <p>Different reference standard (histology of the explanted liver compared to liver biopsy compared to another reference standard). </p> </li> <li> <p>Different liver cirrhosis aetiology: studies with more than 80% participants with viral (hepatitis C or hepatitis B) chronic liver disease compared to studies with less than 80% of participants with viral chronic hepatitis. </p> </li> <li> <p>Different severity of the underlying chronic liver disease: studies with more than 50% of participants with MELD (model for end‐stage liver disease) score less than 15 or with Child Pugh score A compared to studies with less than 50% of participants with MELD less than 15 or Child Pugh score A. </p> </li> </ul> </p> <p>We estimated the above effects by adding covariates to the bivariate models. We assessed the statistical significance of the covariate effect by using the log‐likelihood ratio test for comparison of models with and without the covariate term. </p> </section> <section id="CD013346-sec-0047"> <h4 class="title">Sensitivity analyses</h4> <p>We assessed the effects of risk of bias of the included studies on diagnostic accuracy by performing a sensitivity analysis in which we exclude studies classified as having high or unclear risk of bias in at least one of the domains of QUADAS‐2 (<a href="./appendices#CD013346-sec-0104">Appendix 2</a>). In addition, we defined the following signalling questions as most relevant, and planned to conduct a sensitivity analyses in which we excluded studies with answers of 'no' or 'unclear'. </p> <p> <ul id="CD013346-list-0007"> <li> <p>“Was a case‐control design avoided?” (i.e. was the study design clearly cross‐sectional including a series of participants at risk of with a clinical suspicion of HCC?) </p> </li> <li> <p>For studies using AFP as index test: “if a threshold was used, was it pre‐specified?”; or for ultrasound as index test: “were the positivity criteria defined?”. </p> </li> <li> <p>"Were all participants included in the analysis and analysed according to ITD principle (non‐evaluable results considered as false)?” </p> </li> </ul> </p> <p>We did not perform the planned analysis excluding studies using AFP without a pre‐specified threshold as we chose to analyse the results of studies using the two most common cut‐off values of 20 ng/mL and 200 ng/mL. We did not perform the planned analysis excluding studies not reporting results obtained with ITD principle for uninterpretable results due to lack of data because only two studies reported the number of uninterpretable results. </p> <p>We also conducted, as planned, a sensitivity analysis in which studies published only in abstract or letter form are excluded. </p> </section> <section id="CD013346-sec-0048"> <h4 class="title">Assessment of reporting bias</h4> <p>In order to reduce reporting bias, we did not plan to use a filter search strategy nor to implement any language or sample limitations. We did not plan to test for publication bias due to the lack of validated methods for diagnostic test accuracy reviews. </p> <section id="CD013346-sec-0049"> <h5 class="title">'Summary of findings' table</h5> <p>We prepared 'Summary of findings' tables to present the main results and key information regarding the certainty of evidence, We assessed the certainty of evidence as recommended using the GRADE approach (<a href="./references#CD013346-bbs2-0624" title="SchünemannHJ , OxmanAD , BrozekJ , GlasziouP , JaeschkeR , VistGE , et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (Clinical Research Ed.)2008;336(7653):1106-11.">Schünemann 2008</a>; <a href="./references#CD013346-bbs2-0567" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>; <a href="./references#CD013346-bbs2-0625" title="SchünemannHJ , MustafaR , BrozekJ , SantessoN , Alonso-CoelloP , GuyattG , et al. GRADE Working Group. GRADEGuidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology2016;76:89-98.">Schünemann 2016</a>; <a href="./references#CD013346-bbs2-0590" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 5 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We rated the certainty of evidence as either high (when not downgraded), moderate (when downgraded by one level), low (when downgraded by two levels), or very low (when downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the certainty of evidence started as high when there were high‐quality observational studies (cross‐sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels; (<a href="./references#CD013346-bbs2-0626" title="SchünemannHJ , MustafaR , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al. GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology2020;122:129-41.">Schünemann 2020a</a>; <a href="./references#CD013346-bbs2-0627" title="SchünemannHJ , MustafaR , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al. GRADE guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2020;122:142-52.">Schünemann 2020b</a>)). </p> <p>Five authors (AC, TN, MF, VG, and GC) discussed judgments and applied GRADE In the following way. </p> <p> <ul id="CD013346-list-0008"> <li> <p>Risk of bias: we used QUADAS‐2 to assess risk of bias</p> </li> <li> <p>Indirectness: we assessed indirectness in relation to the population (including disease spectrum), setting, interventions, and outcomes (accuracy measures). We also used prevalence as a guide to whether there was indirectness in the population. </p> </li> <li> <p>Inconsistency: we carried out prespecified analyses to investigate potential sources of heterogeneity and downgraded when we could not explain inconsistency in the accuracy estimates </p> </li> <li> <p>Imprecision: we looked at the confidence intervals of sensitivity and specificity estimates and at the unexplained heterogeneity of the results </p> </li> <li> <p>Publication bias: we did not evaluate publication bias due to the lack of validated methods for diagnostic test accuracy reviews </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013346-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013346-sec-0050"></div> <section id="CD013346-sec-0051"> <h3 class="title" id="CD013346-sec-0051">Results of the search</h3> <p>We ran the search on 5 June 2020. We identified 45,837 records by searching the Cochrane Hepato‐Biliary Group Controlled Trials Register (n = 31), the Cochrane Hepato‐Biliary Group Diagnostic Test Accuracy Register (n = 3), the Cochrane Library (n = 958), MEDLINE Ovid (n = 12,856), Embase Ovid (n = 22,264), LILACS (n = 351), and Science Citation Index Expanded and Conference Proceedings Citation Index – Science (both Web of Science) (n = 9374). We retrieved seven additional records through handsearching. After exclusion of 11,347 duplicates, 34,497 records remained for possible eligibility. After reading the title and the abstract of these records, we excluded 33,932 of them, as they did not meet the inclusion criteria. We retrieved full texts of the remaining 565 records, and after reading the full texts, we excluded 219 studies for various reasons (<a href="#CD013346-fig-0001">Figure 1</a>; <a href="./references#CD013346-sec-0118" title="">Characteristics of excluded studies</a>). In particular, we excluded 109 studies not reporting data or reported only incomplete data on the accuracy of the index tests, 54 studies comparing participants with hepatocellular carcinoma (HCC) with healthy participants or including healthy participants in the control arm, and not reporting the results of the comparison of participants with HCC and participants with chronic liver disease, 31 reporting no original data on the index tests, 10 studies including participants with treated HCC and suspected recurrences, seven studies reporting only per lesion analyses, seven studies not conducted in people with chronic liver disease, and one study (<a href="./references#CD013346-bbs2-0443" title="HeywardWL , LanierAP , McMahonBJ , FitzgeraldMA , KilkennyS , PaprockiTR . Early detection of primary carcinoma. Screening of primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA1985;254(21):3052-4. ">Heyward 1985</a>) reporting preliminary data fully reported in an included study (<a href="./references#CD013346-bbs2-0180" title="McMahonBJ , BulkowL , HarpsterA , SnowballM , LanierA , SaccoF , et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology (Baltimore, Md.)2000;32(4 Pt 1):842-6. ">McMahon 2000</a>). Fourteeen full‐text articles were translated from non English languages, but then excluded (<a href="./references#CD013346-bbs2-0382" title="Del Vecchio-BlancoC , CaporasoN , BalzanoA , GrandeR . Comparative study of the plasma levels of alpha-1 fetoprotein and carcinoembryonic antigen in chronic liver diseases and malignant neoplasias. Quaderni Sclavo di Diagnostica Clinica e di Laboratorio1977;13(3):288-97. ">Del Vecchio‐Blanco 1977</a>; <a href="./references#CD013346-bbs2-0352" title="AburanoT , KuwajimaA , TadaA , IchiyanagiK , TonamiN , HisadaK . Combined use of nuclear medicine and ultrasound in the diagnosis of hepatic tumor (author's transl). Rinsho Hoshasen1979;24(7):729-37. ">Aburano 1979</a>; <a href="./references#CD013346-bbs2-0495" title="MebazaaA , Ben NaceurM , RachdiMT , GarouiH , GargouriM . Diagnostic significance of alpha-fetoproteins in hepatic pathology [Valeur diagnostique du dosage de l'alpha-foeto-protéine en pathologie hépatique]. La Tunisie Medical1985;63(3):237-40. ">Mebazaa 1985</a>; <a href="./references#CD013346-bbs2-0519" title="SalmiA , RangoniG , MartinazzoliF , SalmiR . A clinical study on primary liver cancer in cirrhosis with ascites [Studio clinico del carcinoma epatico primitivo su cirrosi con ascite]. Minerva Dietologica e Gastroenterologica1988;34:163-6. ">Salmi 1988</a>; <a href="./references#CD013346-bbs2-0485" title="LuningM , KochM , AbetL , WolffII , WenigB , BuchaltK , et al. The accuracy of the imaging procedures (sonography, MRT, CT, angio-CT, nuclear medicine) in characterizing liver tumors [Treffsicherheit bildgebender Verfahren (Sonographie, MRT, CT, Angio-CT, Nuklearmedizin) bei der Charakterisierung von Lebertumoren]. Fortschritte Auf Dem Gebiete der Rontgenstrahlen1991;154(4):398-406. ">Luning 1991</a>; <a href="./references#CD013346-bbs2-0518" title="SakaiT , KishikawaY . Follow-up studies on hepatoma developing from liver cirrhosis. Nippon Naika Gakkai Zasshi1991;80(10):1637-44. ">Sakai 1991</a>; <a href="./references#CD013346-bbs2-0364" title="Biwole-SidaM , AmveneN , OyonoE , MbakopA , ManfoC , TapkoJB , et al. Screening of hepatocellular carcinoma in the middle of a high risk population in Cameroon [Dépistage du carcinome hépatocellulaire au sein d'une population de sujets à haut risque au Cameroun]. Annales de Gastroenterologie et d'Hepatologie1992;28(5):213-6. ">Biwole Sida 1992</a>; <a href="./references#CD013346-bbs2-0355" title="BagoJ , BilicA , BabicZ , BabicD , JagicV , AndrijevicB , et al. The role of alpha-fetoprotein in differentiation between primary and secondary liver tumors. Croatian Journal of Gastroenterology and Hepatology1993;2(2):45-8. ">Bago 1993</a>; <a href="./references#CD013346-bbs2-0371" title="Carriere, F, JammetP , LegmannP , HazebroucqV , ParienteD , AbecassisJP , et al. Monitoring of idiopathic liver hemochromatosis. Comparison of ultrasound and MRI in 46 patients [Surveillance hepatique des sujects porteur d'une hemochromatose idiopatique. Compairaison echographie et IRM chez 46 patients]. Revue d'Imagerie Medicale1993;5(4):239-45. ">Carriere 1993</a>; <a href="./references#CD013346-bbs2-0386" title="DingS , LiH , ShunS . Evaluation of the combined assay of alpha-fetoprotein and gamma-glutamyl transpeptidase isoenzyme II in the diagnosis of primary hepatic carcinoma. Zhonghua Nei Ke Za Zhi1995;34(10):690-2. ">Ding 1995</a>; <a href="./references#CD013346-bbs2-0360" title="BeaugrandM . Screening for hepatocellular carcinoma in cirrhotic patients [Depistage du carcinome hepatocellulaire sur cirrhose]. Gastroenterologie Clinique et Biologique2000;24:892-4. ">Beaugrand 2000</a>; <a href="./references#CD013346-bbs2-0359" title="BaumgartenR . Early diagnosis of HCC: how effective are screening examinations [Fruhdiagnose HCC - wie effektiv sin screeninguntersuchungen?]. Die Medizinische Welt2001;52:137-40. ">Baumgarten 2001</a>; <a href="./references#CD013346-bbs2-0361" title="Ben HassineL , DaghfousMH , MamiA , Chammakhi-JemliC , ZouaouiW , SaddoudW , et al. Imaging in the screening and diagnosis of hepatocellular carcinoma in cirrhosis liver in Tunisia. A series of 30 cases [L'imagerie dans le dépistage et le diagnostic du carcinome hépatocellulaire sur foie de cirrhose en Tunisie. A propos de 30 cas]. La Tunisie Medicale2007;85(5):421-6. ">Ben Hassine 2007</a>; <a href="./references#CD013346-bbs2-0417" title="GaoDM , SunL , GuoK , LiY , LiuYK , KangXN . Applicability of the multiplex quantitative antibody array system for early diagnosis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi2012;20(10):785-8. ">Gao 2012</a>). </p> <div class="figure" id="CD013346-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram  Date of search: 5 June 2020" data-id="CD013346-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram <br/>Date of search: 5 June 2020 </p> </div> </div> </div> <p>Finally, we included in our review 346 records reporting data on 373 studies (<a href="#CD013346-fig-0001">Figure 1</a>), including as a whole 168,816 participants, with a percentage of males ranging from 40% to 100% and age ranging from 14 to 97 years. Thirteen papers reported multiple studies in different populations that we quoted and analysed separately as 22 studies (<a href="./references#CD013346-bbs2-0298" title="WangW , LiH , ZhouY , JieS . Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma. Cancer Biomarkers2013;13(5):351-7. ">Wang 2013a</a>; <a href="./references#CD013346-bbs2-0299" title="WangWW , AngSF , KumarR , HeahC , UtamaA , TaniaNP , et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLOS One2013;8(7):e68904. ">Wang 2013b</a>; <a href="./references#CD013346-bbs2-0300" title="WangN , CaoY , SongW , HeK , LiT , WangJ , et al. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis. Journal of Gastroenterology and Hepatology2014;29(7):1544-50. ">Wang 2014a</a>; <a href="./references#CD013346-bbs2-0301" title="WangY , YangH , XuH , LuX , SangX , ZhongS , et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis. Journal of Gastroenterology and Hepatology2014;29(3):597-602. ">Wang 2014b</a>; <a href="./references#CD013346-bbs2-0313" title="WongGL , ChanHL , TseYK , ChanHY , TseCH , LoAO , et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology (Baltimore, Md.)2014;59(3):986-95. ">Wong 2014a</a>; <a href="./references#CD013346-bbs2-0314" title="WongGL , ChanHL , TseYK , ChanHY , TseCH , LoAO , et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology (Baltimore, Md.)2014;59(3):986-95. ">Wong 2014b</a>; <a href="./references#CD013346-bbs2-0062" title="da CostaAN , PlymothA , Santos-SilvaD , Ortiz-CuaranS , CameyS , GuilloreauP , et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. International Journal of Cancer. Journal International du Cancer2015;136:172-81. ">da Costa 2015a</a>; <a href="./references#CD013346-bbs2-0063" title="da CostaAN , PlymothA , Santos-SilvaD , Ortiz-CuaranS , CameyS , GuilloreauP , et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. International Journal of Cancer. Journal International du Cancer2015;136:172-81. ">da Costa 2015b</a>: <a href="./references#CD013346-bbs2-0064" title="da CostaAN , PlymothA , Santos-SilvaD , Ortiz-CuaranS , CameyS , GuilloreauP , et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. International Journal of Cancer. Journal International du Cancer2015;136:172-81. ">da Costa 2015c</a>; <a href="./references#CD013346-bbs2-0065" title="da CostaAN , PlymothA , Santos-SilvaD , Ortiz-CuaranS , CameyS , GuilloreauP , et al. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. International Journal of Cancer. Journal International du Cancer2015;136:172-81. ">da Costa 2015d</a>; <a href="./references#CD013346-bbs2-0146" title="LiL , ChenJ , ChenX , TangJ , GuoH , WangX , et al. Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma. Cancer Letters2016;373(2):234-40. ">Li 2016b</a>, <a href="./references#CD013346-bbs2-0147" title="LiL , ChenJ , ChenX , TangJ , GuoH , WangX , et al. Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma. Cancer Letters2016;373(2):234-40. ">Li 2016c</a>; <a href="./references#CD013346-bbs2-0276" title="TayobN , LokAS , DoKA , FengZ . Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clinical Gastroenterology and Hepatology2016;14(3):469-75. ">Tayob 2016a</a>; <a href="./references#CD013346-bbs2-0277" title="TayobN , LokAS , DoKA , FengZ . Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clinical Gastroenterology and Hepatology2016;14(3):469-75. ">Tayob 2016b</a>; <a href="./references#CD013346-bbs2-0302" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016a</a>, <a href="./references#CD013346-bbs2-0303" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016b</a>; <a href="./references#CD013346-bbs2-0304" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016c</a>; <a href="./references#CD013346-bbs2-0305" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016d</a>; <a href="./references#CD013346-bbs2-0306" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016e</a>; <a href="./references#CD013346-bbs2-0167" title="LuoP , YinP , HuaR , TanY , LiZ , QiuG , et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67(2):662-75. ">Luo 2018a</a>; <a href="./references#CD013346-bbs2-0168" title="LuoP , YinP , HuaR , TanY , LiZ , QiuG , et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67(2):662-75. ">Luo 2018b;</a><a href="./references#CD013346-bbs2-0169" title="LuoP , YinP , HuaR , TanY , LiZ , QiuG , et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67(2):662-75. ">Luo 2018c</a>). We translated six studies from non‐English languages in order to include them in this review (<a href="./references#CD013346-bbs2-0179" title="Mauduit AstolfiL , Nogueira SorianoJM , Talegon MelendezA . Liver cirrhosis and hepatocellular carcinoma. Diagnostic accuracy of ultrasound [Cirrosis hepatica y hepatocarcinoma. Valor diagnostico de la ecografia]. Revista Espanola de Las Enfermedades del Aparato Digestivo1987;72(6):701-4. ">Mauduit Astolfi 1987</a>; <a href="./references#CD013346-bbs2-0038" title="BuffetG , PradesP , HagegeH , CaquilP , InkO , EtienneJP . Focal ultrasonographic lesion on the liver in cirrhotic patients always reflects hepatocellular carcinoma? 217 cases [La lesion echographique focalisee du foie chez le cirrhotique correspond-t-elle toujours a un carcinome hepatocellulaire? 217 observations]. La Presse Medicale1988;17(32):1629-32. ">Buffet 1988</a>; <a href="./references#CD013346-bbs2-0099" title="GarrettiL , FaucigliettiP , ReggeD , BoninoF , BrunettoM , GandiniG . Evaluation of the usefulness of ultrasonics in the diagnosis of cancerous cirrhosis. Comparison with CT [Valutazione dell'ultilità dell'ecotomografia nella diagnosi della cancro-cirrosi]. La Radiologia Medica1988;76:187-92. ">Garretti 1988</a>; <a href="./references#CD013346-bbs2-0143" title="LeeHY , JungJH , KangYS , KimYS , MoonHS , ParkKO , et al. Clinical significance of transiently elevated serum AFP level in developing hepatocellular carcinoma in HBsAg positive-liver cirrhosis. Korean Journal of Gastroenterology2004;43(4):252-9. ">Lee 2004</a>; <a href="./references#CD013346-bbs2-0132" title="KimMJ , BaeKW , SeoPJ , JongKI , KimJH , LeeBH , et al. Optimal cut off value of PIVKAII for the diagnosis of hepatocellular carcinoma--using ROC curve. Korean Journal of Hepatology2006;12(3):404-11. ">Kim 2006c</a>; <a href="./references#CD013346-bbs2-0131" title="KimKA , LeeJS , JungES , KimJY , BaeWK , KimNH , et al. Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development. Korean Journal of Gastroenterololgy2006;48(5):321-6. ">Kim 2006b</a>). Concerning the direction of data collection, 77% (288/373) of the studies were retrospective. </p> <p>We included 326 studies that assessed alpha‐foetoprotein (AFP) as the index test in 144,570 participants; 39 studies that assessed abdominal ultrasound (US) in 18,792 participants; eight studies that assessed both AFP and abdominal US as the index tests in 5454 participants. The studies were conducted since 1971 for AFP, 1983 for abdominal US, and 1988 for the combination of AFP and US. </p> <p>We reported in the <a href="./references#CD013346-sec-0117" title="">Characteristics of included studies</a> tables the main characteristics of the 373 studies. Investigators reported 19 studies only in abstract form, of which 17 with AFP as the index test (<a href="./references#CD013346-bbs2-0256" title="SongJ , KimJ . Significance of alpha fetoprotein in the surveillance of HBV-associated hepatocellular carcinoma. Hepatology (Baltimore, Md.)2011;54(4):1419A. ">Song 2011</a>; <a href="./references#CD013346-bbs2-0054" title="ChengJ , GholamiP , KappusM , SterlingR . Evaluation of diagnostic performance of alpha-fetoprotein (AFP), AFP-l3 and des-gamma-carboxy prothrombin (DCP) for HCV and non-HCV related hepatocellular carcinoma (HCC) after long-term follow-up. American Journal of Gastroenterology2012;107:S145-6. ">Cheng 2012</a>; <a href="./references#CD013346-bbs2-0133" title="KimM , GuGG , KimSY , MinWK . AFP and PIVKA II as surveillance biomarkers for hepatocellular carcinoma. American Journal of Clinical Pathology2012;138:A190. ">Kim 2012</a>; <a href="./references#CD013346-bbs2-0045" title="ChanHLY , WongGL , Lo AngelineOS , WongVW . Revisit of alpha-fetoprotein as a tumor marker for hepatocellular carcinoma in chronic hepatitis B patients receiving entecavir. Hepatology (Baltimore, Md.)2013;58(4 Suppl 1):1256A. ">Chan 2013</a>; <a href="./references#CD013346-bbs2-0291" title="UnicA , GrgurevicI , DerekL , MarijancevicD , SerdarT , RomicZ . AFP-L3 – screening marker for hepatocellular carcinoma in patients with alcoholic cirrhosis. Biochimica Clinica2013;37:S679. ">Unic 2013</a>; <a href="./references#CD013346-bbs2-0182" title="MinB , MoonI , ParkH , JangE , JeongSH , KimJW . Serial measurements do not increase performance of alpha-fetoprotein for hepatocellular carcinoma surveillance in hepatitis B virus-related liver cirrhosis. Journal of Hepatology2014;60:S215–359. ">Min 2014</a>; <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>; <a href="./references#CD013346-bbs2-0128" title="KhairyA , SolimanD , ZayedN , ZakyM , El-AkelW , MedhatE , et al. α-fetoprotein-L3 and simplified hepatocellular carcinoma α-fetoprotein routine test for early detection of hepatocellular carcinoma in Egyptians with liver cirrhosis. Journal of Gastroenterology and Hepatology2015;30(Suppl 4):323-407. ">Khairy 2015</a>; <a href="./references#CD013346-bbs2-0080" title="El-SeragHB , WhiteD , TayobN , AlsarrayA , MoriY , YamadaH , et al. Phase 3 biomarker study for HCC surveillance using AFP, AFP-l3 and DCP: a prospective collection with retrospective blinded evaluation. Hepatology (Baltimore, Md.)2017;66(Suppl 1):754A. ">El‐Serag 2017</a>; <a href="./references#CD013346-bbs2-0206" title="OmarA , OmranD , MahmoudM , El BazT , MedhatE , HosnyA , et al. Hepatocellular cardinoma multidisciplinary clinic – Cairo University (HMC-CU) score; a new simple score for early diagnosis of HCC. United European Gastroenterology2017;5(5S):A184. ">Omar 2017</a>; <a href="./references#CD013346-bbs2-0211" title="ParkYH , HwangS . Diagnostic predictability of blood tumor markers for hepatocellular carcinoma in patients with liver cirrhosis undergoing liver transplantation. 18th Congress of European Society for Organ Transplantation Book of Abstracts2017;30(Suppl 2):286. ">Park 2017b</a>; <a href="./references#CD013346-bbs2-0288" title="TsaiJF , ChenSC , LinZY , DaiCY , YiML , ChuangWL , et al. The optimal cut-off value of serum alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Journal of Hepatology2017;66:S454. ">Tsai 2017</a>; <a href="./references#CD013346-bbs2-0339" title="ZhengY , YangT , SohA , BeshiriA . Application of PIVKA-II in hepatocellular carcinoma diagnosis in Chinese population: preliminary data from Asian multicenter study. Tumor Biology2017;2017:4-5. ">Zheng 2017</a>; <a href="./references#CD013346-bbs2-0005" title="AboelfotohAO , FodaEM , ElghandourAM , Teama NM , AbouzeinRA , MohamedGA . Talin-1, other than a potential marker for hepatocellular carcinoma diagnosis. United European Gastroenterology Journal2018;6(8 Suppl):A566. ">Aboelfotoh 2018</a>; <a href="./references#CD013346-bbs2-0119" title="IyerA , DevdasK , SreeshS , SatharS , SandeshK , SinghAP . To assess the diagnostic accuracy of HCC-alpha fetoprotein-routine test (HCC-ART) score based on age, AFP, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, alkaline phosphatase (ALP), and albumin (Alb) for early detection of hepatocellular carcinoma in cirrhotic patients. Hepatology International2018;12(2):S396. ">Iyer 2018</a>; <a href="./references#CD013346-bbs2-0163" title="LoglioA , IavaroneM , FacchettiF , Di PaoloD , PerbelliniR , LunghiG , et al. The combination of PIVKA-II and AFP levels improves the diagnostic accuracy of HCC diagnosis in long-term NUC suppressed HBV Caucasian cirrhotics. Hepatology (Baltimore, Md.)2018;68(Suppl 1):517A. ">Loglio 2018</a>; <a href="./references#CD013346-bbs2-0270" title="TalkahnM , El SayedEY , FouadMH , GhaitRSA . Evaluation of serum endoglin level as a new diagnostic biomarker for hepatocellular carcinoma. United European Gastroenterology Journal2018;6(8S):A157. ">Talkahn 2018</a>), one with abdominal US as index test (<a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>), and one with both AFP and US as index tests (<a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>). </p> <p>Of the 373 included studies, 190 were conducted in Asia, 66 in Europe, 57 in Africa, 55 in North and South America, and six were collaborative studies in two or three continents. Seventy‐seven studies were conducted in the context of a surveillance program, and 297 studies in participants with clinical suspicion of having an HCC. Two hundred and eighty‐eight studies were conducted retrospectively and 86, prospectively. Three hundred and eight studies used a mix of radiological imaging with or without histology as reference standard, 49 used only histology, and 17 used pathology of the explanted liver. </p> </section> <section id="CD013346-sec-0052"> <h3 class="title">Methodological quality of included studies</h3> <p>We have reported in detail results of the quality assessment of included studies in the <a href="./references#CD013346-sec-0117" title="">Characteristics of included studies</a> tables, and we have summarised this information in <a href="#CD013346-fig-0002">Figure 2</a> and <a href="./appendices#CD013346-sec-0105">Appendix 3</a>. </p> <div class="figure" id="CD013346-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD013346-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> </div> <section id="CD013346-sec-0053"> <h4 class="title">Patient selection domain</h4> <p>Two hundred fifty‐nine studies had a case‐control design, 108 a cross‐sectional design, and six a nested case‐control design (<a href="./references#CD013346-bbs2-0312" title="WongVW , YuJ , ChengAS , WongGL , ChanHY , ChuES , et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. International Journal of Cancer. Journal International du Cancer2009;124(12):2766-70. ">Wong 2009</a>; <a href="./references#CD013346-bbs2-0165" title="LokAS , SterlingRK , EverhartJE , WrightEC , HoefsJC , Di BisceglieAM , et al, HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology2010;138:493-502. ">Lok 2010</a>; <a href="./references#CD013346-bbs2-0305" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016d</a>; <a href="./references#CD013346-bbs2-0332" title="YuR , XiangX , TanZ , ZhouY , WangH , DengG . Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Scientific Reports2016;6:35050. ">Yu 2016</a>; <a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>; <a href="./references#CD013346-bbs2-0278" title="TayobN , ChristieI , RichardsonP , FengZ , WhiteDL , DavilaJ , et al. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis. Clinical Gastroenterology and Hepatology2019;17(9):1886-93. ">Tayob 2019</a>). </p> <section id="CD013346-sec-0054"> <h5 class="title">Alpha‐foetoprotein (AFP)</h5> <p>Risk of bias: we judged 291 of 326 studies assessing the accuracy of AFP, with any cut‐off, to be at high risk of bias. The most common reason was the case‐control design (256 studies). Among the 70 cross‐sectional studies,40 were judged to be at high risk of bias for inappropriate exclusion or for non‐consecutive enrolment of participants. Seventeen studies were at low risk of bias in this domain (<a href="./references#CD013346-bbs2-0017" title="ArrigoniA , AndrulliA , GindroT , PiantinoP , CapussottiL , RizzettoM . Pattern analysis of serum alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma in liver cirrhosis. International Journal of Biological Markers1988;3(3):172-6. ">Arrigoni 1988</a>; <a href="./references#CD013346-bbs2-0059" title="CottoneM , TurriM , CaltagironeM , MaringhiniA , SciarrinoE , VirdoneR , et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alpha fetoprotein: a prospective study. Hepato-gastroenterology1988;35:101-3. ">Cottone 1988</a>; <a href="./references#CD013346-bbs2-0248" title="ShermanM , PeltekianKM , LeeC . Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology (Baltimore, Md.)1995;22(2):432-8. ">Sherman 1995</a>; <a href="./references#CD013346-bbs2-0044" title="ChalasaniN , Horlander JC Sr, SaidA , HoenH , KopeckyKK , Stockberger SM Jr, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. American Journal of Gastroenterology1999;94(10):2988-93. ">Chalasani 1999</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>; <a href="./references#CD013346-bbs2-0116" title="IshiiM , GamaH , ChidaN , UenoY , ShinzawaH , TakagiT , et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. American Journal of Gastroenterology2000;95(4):1036-40. ">Ishii 2000</a>; <a href="./references#CD013346-bbs2-0282" title="TongMJ , BlattLM , KaoVWC . Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. Journal of Gastroenterology and Hepatology2001;16:553-9. ">Tong 2001</a>; <a href="./references#CD013346-bbs2-0177" title="MatievskayaNV , Warwzynowicz-SyzweskaM , TsyrkunovVM , Boropn-KaczmarskaA . Serum alphafetoprotein (AFP) level in patients with chronic HBV and HCV infection. Gastroenerologia Polska2003;10(1):35-40. ">Matievskaya 2003</a>; <a href="./references#CD013346-bbs2-0143" title="LeeHY , JungJH , KangYS , KimYS , MoonHS , ParkKO , et al. Clinical significance of transiently elevated serum AFP level in developing hepatocellular carcinoma in HBsAg positive-liver cirrhosis. Korean Journal of Gastroenterology2004;43(4):252-9. ">Lee 2004</a>; <a href="./references#CD013346-bbs2-0261" title="SterlingRK , JeffersL , GordonF , VenookAP , ReddyKR , SatomuraS , et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clinical Gastroenterology and Hepatology2009;7(1):104-13. ">Sterling 2009</a>; <a href="./references#CD013346-bbs2-0256" title="SongJ , KimJ . Significance of alpha fetoprotein in the surveillance of HBV-associated hepatocellular carcinoma. Hepatology (Baltimore, Md.)2011;54(4):1419A. ">Song 2011</a>; <a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0262" title="SterlingRK , WrightEC , MorganTR , SeeffLB , HoefsJC , Di BisceglieAM , et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. American Journal of Gastroenterology2012;107(1):64-74. ">Sterling 2012</a>; <a href="./references#CD013346-bbs2-0276" title="TayobN , LokAS , DoKA , FengZ . Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clinical Gastroenterology and Hepatology2016;14(3):469-75. ">Tayob 2016a</a>; <a href="./references#CD013346-bbs2-0277" title="TayobN , LokAS , DoKA , FengZ . Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clinical Gastroenterology and Hepatology2016;14(3):469-75. ">Tayob 2016b</a>; <a href="./references#CD013346-bbs2-0303" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016b</a>; <a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>). Among the 147 studies using 20 ng/mL as a cut‐off value, we judged 129 studies to be at high risk of bias and 12 at unclear risk of bias; among the 56 studies using AFP with a cut‐off value of 200 ng/mL, we judged 48 studies to be at high risk of bias. </p> <p>Applicability: we judged 273 studies to be at high concern because study participants were highly selected on the basis of aetiology or severity of the liver diease and HCC characteristics. Among the 147 studies using 20 ng/mL as a cut‐off value, we judged 115 studies to be at high concern; among the 56 studies using AFP with a cut‐off value of 200 ng/mL, we judged 47 studies to be at high concern. </p> </section> <section id="CD013346-sec-0055"> <h5 class="title">Abdominal ultrasound (US)</h5> <p>Risk of bias: 21 of the 39 studies assessing the accuracy of abdominal US were judged to be at high risk of bias: three studies were case‐control studies (<a href="./references#CD013346-bbs2-0222" title="Powell-JacksonP , ForbesA , MichellM , WilliamsR . Effect of cirrhosis on accuracy of 99Tcm-tin colloid scintigraphy and ultrasound scanning in diagnosis of hepatocellular carcinoma. British Journal of Radiology1987;60(720):1221-2. ">Powell‐Jackson 1987</a>; <a href="./references#CD013346-bbs2-0121" title="JalliR , JafariSH , SefidbakhtS , KazemiK . Comparison of the accuracy of DWI and ultrasonography in screening hepatocellular carcinoma in patients with chronic liver disease. Iran Journal of Radiology2015;12(1):e12708. ">Jalli 2015</a>; <a href="./references#CD013346-bbs2-0554" title="YangT , XingH , WangG , WangN , LiuM , YanC , et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clinical Chemistry2019;65(12):1543–53. ">Yang 2019</a>), and the remaining 18 were cross‐sectional studies. The risk of bias was judged as high because of inappropriate exclusion or for non‐consecutive enrolment of participants. Two studies were judged to be at unclear risk of bias for the latter domain as they did not report any exclusion criteria (<a href="./references#CD013346-bbs2-0214" title="PateronD , GanneN , TrinchetJC , AurousseauMH , MalF , MeiclerC , et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. Journal of Hepatology1994;20(1):65-71. ">Pateron 1994</a>; <a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>). </p> <p>Applicability: we judged 22 studies at high concern as participants were highly selected on the basis of aetiology or severity of the liver diease and HCC characteristics. </p> </section> <section id="CD013346-sec-0056"> <h5 class="title">Combination of AFP and abdominal (US)</h5> <p>Risk of bias: of the eight studies assessing the accuracy of the combination of AFP and abdominal US, three studies were judged at high risk of bias for inappropriate exclusion or for non‐consecutive enrolment of participants (<a href="./references#CD013346-bbs2-0038" title="BuffetG , PradesP , HagegeH , CaquilP , InkO , EtienneJP . Focal ultrasonographic lesion on the liver in cirrhotic patients always reflects hepatocellular carcinoma? 217 cases [La lesion echographique focalisee du foie chez le cirrhotique correspond-t-elle toujours a un carcinome hepatocellulaire? 217 observations]. La Presse Medicale1988;17(32):1629-32. ">Buffet 1988</a>; <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>). <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a> and <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a> used AFP with a cut‐off of 20 ng/mL. All the eight studies were cross‐sectional. </p> <p>Applicability: we judged two studies to be at high concern, both of which with AFP cut‐off value of 20 ng/mL, as only participants with severe liver disease on waiting list for orthotopic liver transplantation were included (<a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>). </p> </section> </section> <section id="CD013346-sec-0057"> <h4 class="title">Index tests domain</h4> <section id="CD013346-sec-0058"> <h5 class="title">Alpha‐foetoprotein (AFP)</h5> <p>Risk of bias: we judged a total of 196 studies to be at high risk of bias. In 128 studies, no pre‐definition of a cut‐off value was reported. In 122 studies, the result of AFP measurement was interpreted knowing the result of the reference standard, and in 47 studies, it was unclear. Among the 147 studies using 20 ng/mL as a cut‐off value, we judged 73 studies to be at high risk of bias; among the 56 studies using AFP wit a cut‐off value of 200 ng/mL, we judged 54 studies to be at high risk of bias. </p> <p>Applicabilty: we judged 10 studies to be at high concern due to variations in test technology, execution or interpretation (<a href="./references#CD013346-bbs2-0012" title="AlpertE , HershbergR , ShurPH , IsselbacherKJ . Alpha -fetoprotein in human hepatoma: improved detection in serum, and quantitative studies using a new sensitive technique. Gastroenterology1971;61(2):137-43. ">Alpert 1971</a>; <a href="./references#CD013346-bbs2-0102" title="GiannelliG , MarinosciF , TrerotoliP , VolpeA , QuarantaM , DenticoP , et al. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. International Journal of Cancer. Journal International du Cancer2005;117(3):506-9. ">Giannelli 2005</a>; <a href="./references#CD013346-bbs2-0272" title="TanY , GeG , PanT , WenD , ChenL , YuX , et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLOS One2014;9(9):e107986. ">Tan 2014</a>; <a href="./references#CD013346-bbs2-0301" title="WangY , YangH , XuH , LuX , SangX , ZhongS , et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis. Journal of Gastroenterology and Hepatology2014;29(3):597-602. ">Wang 2014b</a>; <a href="./references#CD013346-bbs2-0303" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016b</a>; <a href="./references#CD013346-bbs2-0304" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016c</a>; <a href="./references#CD013346-bbs2-0305" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016d</a>; <a href="./references#CD013346-bbs2-0306" title="WangM , DevarajanK , SingalAG , MarreroJA , DaiJ , FengZ , et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prevention Research (Philadelphia, Pa.)2016;9(2):172-9. ">Wang 2016e</a>; <a href="./references#CD013346-bbs2-0308" title="WangQ , ChenQ , ZhangX , LuXL , DuQ , ZhuT , et al. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology2019;25(36):5515-29. ">Wang 2019a</a>; <a href="./references#CD013346-bbs2-0265" title="SunQ , LiJ , JinB , WangT , GuJ . Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis C virus-related hepatocellular carcinoma at early stage. Clinics and Research in Hepatology and Gastroenterology2020;44(1):21-8. ">Sun 2020</a>). All the studies using AFP with a cut‐off value of 20 ng/mL or 200 ng/mL were at low concern. </p> </section> <section id="CD013346-sec-0059"> <h5 class="title">Abdominal ultrasound (US)</h5> <p>Risk of bias: we judged 16 studies to be at high risk of bias as no definition of positivity criteria was reported (<a href="./references#CD013346-bbs2-0205" title="OkazakiN , YoshidaT , YoshinoM , MatueH . Screening of patients with chronic liver disease for hepatocellular carcinoma by ultrasonography. Clinical Oncology1984;10:241-6. ">Okazaki 1984</a>; <a href="./references#CD013346-bbs2-0273" title="TanakaS , KitamuraT , OhshimaA , UmedaK , OkudaS , OhtaniT , et al. Diagnostic accuracy of ultrasonography for hepatocellular carcinoma. Cancer1986;588:344-7. ">Tanaka 1986</a>; <a href="./references#CD013346-bbs2-0059" title="CottoneM , TurriM , CaltagironeM , MaringhiniA , SciarrinoE , VirdoneR , et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alpha fetoprotein: a prospective study. Hepato-gastroenterology1988;35:101-3. ">Cottone 1988</a>; <a href="./references#CD013346-bbs2-0099" title="GarrettiL , FaucigliettiP , ReggeD , BoninoF , BrunettoM , GandiniG . Evaluation of the usefulness of ultrasonics in the diagnosis of cancerous cirrhosis. Comparison with CT [Valutazione dell'ultilità dell'ecotomografia nella diagnosi della cancro-cirrosi]. La Radiologia Medica1988;76:187-92. ">Garretti 1988</a>; <a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0229" title="SaadaJ , BhattacharyaS , DhillonAP , DickR , BurroughsAK , RollesK , et al. Detection of small hepatocellular carcinomas in cirrhotic livers using iodised oil computed tomography. Gut1997;41:404-7. ">Saada 1997</a>; <a href="./references#CD013346-bbs2-0331" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>; <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>; <a href="./references#CD013346-bbs2-0121" title="JalliR , JafariSH , SefidbakhtS , KazemiK . Comparison of the accuracy of DWI and ultrasonography in screening hepatocellular carcinoma in patients with chronic liver disease. Iran Journal of Radiology2015;12(1):e12708. ">Jalli 2015</a>; <a href="./references#CD013346-bbs2-0217" title="PineroF , MarcianoS , AndersM , OrozcoF , ZeregaA , CabreraCR , et al. Screening for liver cancer during transplant waiting list: a multicenter study from South America. European Journal of Gastroenterology &amp; Hepatology2015;27(3):355-60. ">Pinero 2015</a>; <a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>; <a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>; <a href="./references#CD013346-bbs2-0141" title="KudoM , UeshimaK , OsakiY , HirookaM , ImaiY , AsoK , et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer2019;8(4):271-80. ">Kudo 2019</a>; <a href="./references#CD013346-bbs2-0554" title="YangT , XingH , WangG , WangN , LiuM , YanC , et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clinical Chemistry2019;65(12):1543–53. ">Yang 2019</a>). </p> <p>Applicability: we judged all the 39 studies to be at low concern.</p> </section> <section id="CD013346-sec-0060"> <h5 class="title">Combination of AFP and abdominal US</h5> <p>Risk of bias: we judged three studies, two with a cut‐off value of 20 ng/mL (<a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>), and one with a cut‐off value of 5 ng/mL (<a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>) to be at high risk of bias as no definition of US positivity criteria was reported. </p> <p>Applciability: we judged all eight studies to be at low concern.</p> </section> </section> <section id="CD013346-sec-0061"> <h4 class="title">Reference standard domain</h4> <section id="CD013346-sec-0062"> <h5 class="title">Alpha‐foetoprotein (AFP)</h5> <p>Risk of bias: we judged 174 studies to be at high risk of bias. In 105 studies with a case‐control design, the reference standard was not adequate to exclude the presence of HCC, and in 24 studies, authors reported only how they assessed the presence of a chronic liver disease without any information concerning the target disease. In 100 studies, the reference standard was interpreted knowing the results of the index test, and in 43 studies we judged the available information to be insufficient. </p> <p>Applicability: we judged 55 studies to be at high concern as pathological examination of explanted liver, or of surgical specimen, or necroscopy, or technologies that were no longer in use, were required to confirm the presence of HCC. </p> </section> <section id="CD013346-sec-0063"> <h5 class="title">Abdominal ultrasound (US)</h5> <p>Risk of bias: we judged 23 studies to be at high risk of bias. In 20 studies, the reference standard was interpreted knowing the results of the index test, and in 11 studies the reference standard was judged to be inadequate to exclude the absence of HCC. </p> <p>Applicability: we judged 13 studies to be at high concern as pathological examination of explanted liver, or of surgical specimen, or necroscopy, or technologies no longer in use, were required to confirm the presence of HCC. </p> </section> <section id="CD013346-sec-0064"> <h5 class="title">Combination of AFP and abdominal US</h5> <p>Risk of bias: we judged five studies to be at high risk of bias, four using AFP with cut‐off 20 ng/mL (<a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>) and one with a cut‐off of 250 ng/mL (<a href="./references#CD013346-bbs2-0038" title="BuffetG , PradesP , HagegeH , CaquilP , InkO , EtienneJP . Focal ultrasonographic lesion on the liver in cirrhotic patients always reflects hepatocellular carcinoma? 217 cases [La lesion echographique focalisee du foie chez le cirrhotique correspond-t-elle toujours a un carcinome hepatocellulaire? 217 observations]. La Presse Medicale1988;17(32):1629-32. ">Buffet 1988</a>). In these studies, the reference standard was interpreted knowing the results of the index test and was judged inadequate to exclude the absence of HCC. </p> <p>Applicability: we judged two studies to be at high concern as the reference standard was the pathological examination of explanted liver (<a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>) or histology and arteriography (<a href="./references#CD013346-bbs2-0038" title="BuffetG , PradesP , HagegeH , CaquilP , InkO , EtienneJP . Focal ultrasonographic lesion on the liver in cirrhotic patients always reflects hepatocellular carcinoma? 217 cases [La lesion echographique focalisee du foie chez le cirrhotique correspond-t-elle toujours a un carcinome hepatocellulaire? 217 observations]. La Presse Medicale1988;17(32):1629-32. ">Buffet 1988</a>). Of these two studies, <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a> used AFP with a cut‐off value of 20 ng/mL. </p> </section> </section> <section id="CD013346-sec-0065"> <h4 class="title">Flow and timing domain</h4> <section id="CD013346-sec-0066"> <h5 class="title">Alpha‐foetoprotein (AFP)</h5> <p>Risk of bias: we judged 263 studies to be at high risk of bias. In 259 studies, participants did not receive the same reference standard. In six studies, the time interval between the index test and the reference standard was judged to be too long, whereas in other 305 studies, this information was not reported. </p> </section> <section id="CD013346-sec-0067"> <h5 class="title">Abdominal ultrasound (US)</h5> <p>Risk of bias: we judged at high risk of bias 27 studies: in 22 studies participants did not receive the same reference standard. In six studies, the time interval between the index test and the reference standard was judged to be too long, whereas in other 25 studies, this information was not reported. Two studies reported the proportion of uninterpretable results (<a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>, 56/523 and <a href="./references#CD013346-bbs2-0172" title="MaringhiniA , CottoneM , SciarrinoE , MarcenóMP , La SetaF , FuscoG , et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Digestive Diseases and Sciences1988;33(1):47-51. ">Maringhini 1988</a>, 28/363), allowing an analysis according to the intention‐to‐diagnose principle, and another study included in the analyses uninterpretable results (<a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>). </p> </section> <section id="CD013346-sec-0068"> <h5 class="title">Combination of AFP and abdominal US</h5> <p>Risk of bias: we judged six studies to be at high risk of bias (<a href="./references#CD013346-bbs2-0038" title="BuffetG , PradesP , HagegeH , CaquilP , InkO , EtienneJP . Focal ultrasonographic lesion on the liver in cirrhotic patients always reflects hepatocellular carcinoma? 217 cases [La lesion echographique focalisee du foie chez le cirrhotique correspond-t-elle toujours a un carcinome hepatocellulaire? 217 observations]. La Presse Medicale1988;17(32):1629-32. ">Buffet 1988</a>; <a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>). In five studies, participants did not receive the same reference standard,and in five studies, there was no information on the time interval between the index test and the reference standard. We judged one study to be at unclear risk of bias (<a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>), and one study to be at low risk of bias (<a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>). Of the six studies using AFP with cut‐off 20 ng/mL, five were at high risk of bias and one at unclear risk of bias. </p> </section> </section> <section id="CD013346-sec-0069"> <h4 class="title">Overall assessment</h4> <p>As shown in <a href="#CD013346-fig-0002">Figure 2</a>, we judged 304 studies at high risk of bias and 13 studies at unclear risk for the patient selection domain. For the index test domain, 196 studies with AFP were judged at high risk of bias and 23 at unclear risk; 16 studies with US were judged at high risk, and three studies with combination of AFP and US were judged at high risk. For the reference standard domain, 184 studies were judged at high risk of bias and 47 at unclear risk. For the flow and timing domain, 276 studies were judged at high risk of bias and 53 at unclear risk. We classified a study as having a high risk of bias if at least one of the domains of QUADAS‐2 was judged as being at high or unclear risk of bias (<a href="#CD013346-sec-0023">Methods</a>). We judged only one study to be at low risk of bias (<a href="./references#CD013346-bbs2-0030" title="BennettGL , KrinskyGA , AbitbolRJ , KimSY , TheiseND , TepermanLW . Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis:Correlation of pre transplantation sonography and liver explant pathology in 200 patients. AJR. American Journal of Roentgenology2002;179:75-80. ">Bennett 2002</a>): this study was retrospectively conducted in a series of consecutive participants who underwent liver transplantation. The index test was abdominal US performed according to predefined positivity criteria and performed less than 90 days earlier, and the reference standard was the pathological examination of the explanted liver. </p> <p>Concerning applicability, for the patient selection domain we judged at high concern 289 studies; for the index test domain 10 studies using AFP were judged at high concern, none using US or combination of AFP and US; for the reference standard domain 60 studies were judged at high concern and 10 at unclear concern. </p> </section> </section> <section id="CD013346-sec-0070"> <h3 class="title" id="CD013346-sec-0070">Findings</h3> <section id="CD013346-sec-0071"> <h4 class="title">Alpha‐foetoprotein (AFP)</h4> <section id="CD013346-sec-0072"> <h5 class="title">Description of the included studies</h5> <p>Three hundred and twenty‐six studies with 144,570 participants provided data assessing serum alpha‐foetoprotein (AFP) measurement for the diagnosis of HCC. The median prevalence of the target disease was 50% (interquartile range (IQR) 33% to 59%). When considering only the 70 cross‐sectional studies, the median prevalence was 16% (IQR 9% to 33%). The cut‐off values ranged from 5 ng/mL to 1000 ng/mL. The median prevalence of cirrhosis was 100% (IQR 73% to 100%). The median of the proportion of participants in Child‐Pugh class A was 61% (IQR 38% to 82%) while the median proportion of participants with viral aetiology was 100% (IQR 76% to 100%). The median proportion of resectable HCC was 57% (IQR 34% to 91%) and the median of the mean HCC diameter across studies was 29.5 mm (IQR 20.5 mm to 46 mm). The studies were conducted from 1971 to 2020. Considering study location, 174 studies were conducted in Asia, 57 in Africa, 52 in Europe, 39 in North and South America, and four in more than one continent. Fifty studies were conducted in the context of a surveillance programme for HCC and 276 in a clinical setting. </p> </section> <section id="CD013346-sec-0073"> <h5 class="title">Pooled results</h5> <p><a href="./appendices#CD013346-sec-0106">Appendix 4</a> shows a forest plot of sensitivity and specificity with their 95% confidence intervals (CIs), and <a href="#CD013346-fig-0003">Figure 3</a> shows a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). We performed a meta‐analysis using the hierarchical summary ROC model (HSROC) as the primary studies reported accuracy estimates of AFP using different cut‐off values (<a href="#CD013346-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD013346-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) comparing in 326 studies alpha‐foetoprotein serum measurement with any cut‐off value and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months." data-id="CD013346-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing in 326 studies alpha‐foetoprotein serum measurement with any cut‐off value and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> </div> </div> </div> <p>We then carried out two meta‐analyses that included only studies that reported a cut‐off value of 20 ng/mL or 200 ng/mL (the most used values). </p> </section> </section> <section id="CD013346-sec-0074"> <h4 class="title">AFP cut‐off value around 20 ng/mL</h4> <section id="CD013346-sec-0075"> <h5 class="title">Description of the included studies</h5> <p>One hundred forty seven studies with 52,144 participants provided data using a cut‐off value of around 20 ng/mL (from 19 to 21 ng/mL). Five studies were published only in abstract form; 111 were case‐control studies. The median prevalence of HCC across studies was 50% (IQR 33% to 63%). When considering only the 32 cross‐sectional studies, the median prevalence was 11% (IQR 7% to 20%). The median proportion of participants with liver cirrhosis was 100% (data reported by 96 studies, IQR 75% to 100%), and the median prevalence of participants in Child‐Pugh class A was 67% (51 studies, IQR 43% to 82%). The median proportion of participants with viral aetiology of cirrhosis was 97% (119 studies, IQR 78% to 100%) and the median of mean HCC across studies diameter was 27 mm (20 studies, IQR 22.5 to 46.5 mm). Finally, the median of participants with resectable HCC was 59% (29 studies, IQR 42% to 87%). The studies were conducted from 1982 to 2020. Considering study location, 98 were conducted in Asia, 22 in Europe, 7 in Africa, 19 in North and South America, and one in three continents. Thirty studies were conducted in the context of a surveillance programme for HCC and 117 in a clinical setting. The sensitivity varied from 25% to 90% (IQR from 53% to 67%) and the specificity from 35% to 100% (IQR from 76% to 90%; <a href="#CD013346-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD013346-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 20 ng/mL against different reference standards in 147 studies ordered by study design, setting and increasing HCC prevalence. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD013346-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 20 ng/mL against different reference standards in 147 studies ordered by study design, setting and increasing HCC prevalence. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> </div> </section> <section id="CD013346-sec-0076"> <h5 class="title">Pooled results</h5> <p>By using the bivariate model, we obtained the following pooled estimates: sensitivity 60% (95% CI 58% to 62%), specificity 84% (95% CI 82% to 86%), LR+ 3.84 (95% CI 3.39 to 4.33), LR‐ 0.48 (95% CI 0.45 to 0.50; <a href="#CD013346-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD013346-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) comparing alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and alpha‐foetoprotein with a cut‐off value around 200 ng/mL (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for AFP cut‐off around 20 ng/ml (black circle) and AFP cut off 200 ng/ml (red circle).The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and alpha‐foetoprotein with a cut‐off value around 200 ng/mL (red diamonds) against the same reference standards.<br/>Reference standards were: the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for AFP cut‐off around 20 ng/ml (black circle) and AFP cut off 200 ng/ml (red circle). </p> <p>The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> </div> <p>In the 30 studies conducted in a surveillance programme, the pooled sensitivity was 54% (95% CI 59% to 63%) and specificity 83% (95% CI 84% to 85%); in the 117 studies conducted in a clinical setting, the pooled sensitivity was 61% (95% CI 59% to 63%) and the specificity 83% (95% CI 84% to 85%; <a href="#CD013346-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD013346-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) comparing the results of studies conducted in different settings, surveillance programs (black circles) and clinical setting (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for surveillance setting (black circle) and clinical suspect setting (red circle).The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing the results of studies conducted in different settings, surveillance programs (black circles) and clinical setting (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for surveillance setting (black circle) and clinical suspect setting (red circle). </p> <p>The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> </div> <p>We assessed the diagnostic accuracy for resectable HCC as a secondary objective. We found six studies with 1722 participants with more than 90% of participants with resectable HCC (<a href="./references#CD013346-bbs2-0200" title="NomuraF , IshijimaM , HorikoshiA , NakaiT , OhnishiK . Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. American Journal of Gastroenterology1996;91(7):1380-3. ">Nomura 1996</a>; <a href="./references#CD013346-bbs2-0201" title="NomuraF , IshijimaM , KuwaK , TanakaN , NakaiT , OhnishiK . Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. American Journal of Gastroenterology1999;94(3):650-4. ">Nomura 1999</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>; <a href="./references#CD013346-bbs2-0247" title="ShenQ , FanJ , YangXR , TanY , ZhaoW , XuY , et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncology2012;13(8):817-26. ">Shen 2012b</a>; <a href="./references#CD013346-bbs2-0271" title="TanY , YinP , TangL , XingW , HuangQ , CaoD , et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Molecular &amp; Cellular Proteomics2012;11(2):M111.010694. ">Tan 2012</a>; <a href="./references#CD013346-bbs2-0257" title="SongP , FengX , InagakiY , SongT , ZhangK , WangZ , et al. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: a multi-center case-controlled study of 1,153 subjects. Bioscience Trends2014;8(5):266-73. ">Song 2014</a>). By using the bivariate model, the sensitivity was 65% (95% CI 62% to 68%), the specificity 80% (95% CI 59% to 91%), LR+ 3.2 (95% CI 1.4 to 7.2) and LR‐ 0.44 (95% CI 0.34 to 0.56). </p> <p><b>Heterogeneity analysis</b> </p> <p>We investigated heterogeneity while considering studies with AFP cut‐off values around 20 ng/mL. <a href="#CD013346-tbl-0004">Table 2</a> shows the comparisons of different predefined subgroups. The estimates of sensitivity and specificity were different only for the comparison of studies including participants recruited from planned surveillance programs compared to clinical cohorts (P = 0.005). </p> <div class="table" id="CD013346-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 20 ng/mL</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (81% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% (52% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (84% to 91%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (54% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86% (81% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.828</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% (59% to 71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (81% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.264</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (56% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (82% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (51% to 70%)*</p> <p>57% (50% to 63%)**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (84% to 90%)*</p> <p>83% (74% to 90%)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (54% to 65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (83% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (50% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (85% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (80%to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (54% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (71% to 89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (47% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (84% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.147</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (81% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (59% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (80% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (49% to 60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (86% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (48% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (64% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.909</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (51% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (81% to 91%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (58% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (77% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.832</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (82% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (55% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (83% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.694</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (81% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (52% to 67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86% (82%to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.746</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (55% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (77% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>* <a href="./references#CD013346-bbs2-0107" title="HallagerS , LadelundS , KjaerM , MadsenLG , BelardE , LaursenAL , et al. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study. Journal of Viral Hepatitis2018;25(1):47-55. ">Hallager 2018</a> ; ** <a href="./references#CD013346-bbs2-0159" title="LiuXY , FanYC , GaoS , ZhaoJ , ChenLY , LiF , et al. Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma. Neoplasma2017;64(5):745-53. ">Liu 2017</a> </p> <p>§ Model failed to converge</p> <p><b>HCC</b>: hepatocellular carcinoma </p> </div> </div> <p><b>Sensitivity analysis</b> </p> <p>When considering only the 36 studies with a cross‐sectional design, we obtained an AFP sensitivity of 57% (95% CI 52% to 62%) and specificity of 88% (95% CI 84% to 91%; <a href="#CD013346-tbl-0004">Table 2</a>). When considering the 142 studies published in full text, we obtained an AFP sensitivity of 60% (95% CI 58% to 62%) and specificity of 84% (95% CI 82% to 86%; <a href="#CD013346-tbl-0004">Table 2</a>). We did not perform the remaining sensitivity analyses as all studies were judged to be at high risk of bias, and no study reported uninterpretable results. </p> </section> </section> <section id="CD013346-sec-0077"> <h4 class="title">AFP cut‐off value 200 ng/mL</h4> <section id="CD013346-sec-0078"> <h5 class="title">Description of the included studies</h5> <p>Fifty‐six studies with 20,452 participants provided data using a cut‐off value of 200 ng/mL. </p> <p>Two studies were published only in abstract form, 42 were case‐control studies. The median prevalence of HCC was 51% (IQR 34% to 63%). When considering only the 14 cross‐sectional studies, the median prevalence was 21% (IQR 9% to 34%). The median proportion of participants with liver cirrhosis was 100% (data reported by 41 studies, IQR 92% to 100%) and the median prevalence of Child‐Pugh class A participants was 47% (24 studies, IQR 32% to 77%); the median proportion of participants with viral aetiology of cirrhosis was 100% (41 studies, IQR 79% to 100%); the median of the mean HCC diameter across studies was 31 mm (10 studies, IQR 20 mm to 42 mm). The median prevalence of resectable HCC was 51% (10 studies, IQR 36% to 73%). The studies were conducted from 1988 to 2018. Considering study location, 31 studies were conducted in Asia, nine in Africa, nine in North and South America, and eight in Europe, Seven studies were conducted in the context of a surveillance programme for HCC and 49 in a clinical setting. Sensitivity varied from 4% to 83% (IQR 23% to 50%) and specificity from 87% to 100% (IQR from 97% to 100%; <a href="./appendices#CD013346-sec-0107">Appendix 5</a>). </p> </section> <section id="CD013346-sec-0079"> <h5 class="title">Pooled results</h5> <p>By using the bivariate model, we obtained the following estimates: sensitivity 36% (95% CI 31% to 41%), specificity 99% (95% CI 98% to 100%), LR+ 35.9 (95% CI 22.2 to 57.9) LR‐ 0.64 (95% CI 0.60 to 0.695; <a href="#CD013346-fig-0005">Figure 5</a>). </p> <p>We assessed the diagnostic accuracy for resectable HCC as a secondary objective. We found only two studies with more than 90% of participants with resectable HCC, preventing a meta‐analysis of their results: <a href="./references#CD013346-bbs2-0200" title="NomuraF , IshijimaM , HorikoshiA , NakaiT , OhnishiK . Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. American Journal of Gastroenterology1996;91(7):1380-3. ">Nomura 1996</a>, with 128 participants, reported a sensitivity of 4% (95% CI 0% to 19%) and a specificity of 100% (95% CI 96% to 100%) and <a href="./references#CD013346-bbs2-0236" title="SassaT , KumadaT , NakanoS , UematsuT . Clinical utility of simultaneous measurement of serum high sensitivity des-gamma-carboxy-prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoptrotein in patient with small hepatocellular carcinoma. European Journal of Gastroentrology &amp; Hepatology1999;11:1387-92. ">Sassa 1999</a>, with 195 participants, reported a sensitivity of 8% (95% CI 3% to 18%) and a specificity of 100% (95% CI 97% to 100%). </p> <p><b>Heterogeneity analysis</b> </p> <p>We investigated heterogeneity while considering studies with AFP cut‐off value of 200 ng/mL. <a href="#CD013346-tbl-0005">Table 3</a> shows the comparisons of different predefined subgroups. The estimates of sensitivity and specificity were different for the comparison of studies conducted in different continents; and also for studies including more than 50% of participants in Chil‐Pugh class A compared to studies including less than 50% in Child‐Pugh class A. </p> <div class="table" id="CD013346-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 200 ng/mL</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (31% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% (30% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.874</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39% (28% to 51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (27% to 58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.713</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% (30% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28% (15% to 47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.336</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (33% to 42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (28% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (99% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (28% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.020</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% (21% to 35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% (29% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98% (97% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53% (39% to 66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% (16% to 48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.805</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (32% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (32% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.995</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% (18% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (96% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (8% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (82% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.931</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% (12% to 50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% (24% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (32% to 43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (29% to 46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.705</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% (26% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (31% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (99% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24% (19% to 29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (31% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>HCC</b>: hepatocellular carcinoma </p> </div> </div> <p><b>Sensitivity analysis</b> </p> <p>When considering only the 14 studies with a cross‐sectional design, we obtained an AFP sensitivity of 39% (95% CI 28% to 51%) and a specificity of 99% (95% CI 98% to 99%; <a href="#CD013346-tbl-0005">Table 3</a>). </p> <p>When considering the 54 studies published in full text and excluding the two published in abstract form, we obtained an AFP sensitivity of 36% (95% CI 31% to 41%) and a specificity of 99% (95% CI 98% to 100%; <a href="#CD013346-tbl-0005">Table 3</a>), </p> <p>We did not perform the remaining sensitivity analyses as all studies were judged to be at high risk of bias, and no study reported uninterpretable results. </p> </section> <section id="CD013346-sec-0080"> <h5 class="title">Abdominal ultrasound (US)</h5> <section id="CD013346-sec-0081"> <h6 class="title">Description of the included studies</h6> <p>Thirty‐nine studies with 18,792 participants provided data assessing abdominal ultrasound (US) for the diagnosis of HCC. </p> <p>The median prevalence of the target disease was 15% (interquartile range 8% to 31%). When considering the 36 cross‐sectional studies, the median prevalence of HCC was 15% (IQR 9% to 25%). All included participants had hepatic cirrhosis. The median prevalence of Child‐Pugh class A participants was 69% (14 studies, IQR 30% to 81%), and the median proportion of participants with viral aetiology was 60% (26 studies, IQR 40% to 84%). The median proportion of participants with resectable HCC was 76% (20 studies, IQR 40% to 95%) and the median of the mean diameter across studies was 24 mm (17 studies, IQR 20.5 mm to 31 mm). The studies were conducted from 1983 to 2020. Considering study location, 13 studies were conducted in North and South America, 13 in Asia, 12 in Europe, and one in three continents. Twenty studies were conducted in the context of a surveillance program for HCC and 19 in participants with clinical suspected HCC. </p> </section> <section id="CD013346-sec-0082"> <h6 class="title">Pooled results</h6> <p><a href="#CD013346-fig-0007">Figure 7</a> shows the forest plot of sensitivity and specificity with their 95% CIs, and <a href="#CD013346-fig-0008">Figure 8</a> shows a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). Sensitivity ranged from 28% to 100% (IQR 44% to 89%) and specificity from 43% to 100% (IQR 86% to 96%). We performed a meta‐analysis using the bivariate model, as the index test results are dichotomous (i.e. positive or negative) without a threshold. We obtained the following estimates: sensitivity 72% (95% CI 63% to 79%), specificity 94% (95% CI 91% to 96%), LR+ 12.5 (95% CI 8.6 to 18.25), LR‐ 0.29 (95% CI 0.22 to 0.39). </p> <div class="figure" id="CD013346-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plots of sensitivity and specificity of ultrasound against different reference standards.in 39 studies. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).The individual studies are ordered by study design (cross‐sectional or case‐control), study setting (clinical setting or surveillance program) and increasing sensitivity." data-id="CD013346-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of ultrasound against different reference standards.in 39 studies. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).The individual studies are ordered by study design (cross‐sectional or case‐control), study setting (clinical setting or surveillance program) and increasing sensitivity. </p> </div> </div> </div> <div class="figure" id="CD013346-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) comparing, in 39 studies, ultrasound and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circle represents the summary estimate of sensitivity and specificity.The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing, in 39 studies, ultrasound and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circle represents the summary estimate of sensitivity and specificity.The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> </div> <p>We assessed the diagnostic accuracy for resectable HCC as a secondary objective. We found seven studies (2163 participants) with more than 90% with resectable HCC (<a href="./references#CD013346-bbs2-0067" title="DoddGD , MillerWJ , BaronLR , SclonickML , CampbellWL . Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR. American Journal of Roentgenology1992;159:727-33. ">Dodd 1992</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>; <a href="./references#CD013346-bbs2-0129" title="KimCK , LimJH , LeeWJ . Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver accuracy of ultrasonography in transplant patients. Journal of Ultrasound in Medicine2001;20:99-104. ">Kim 2001</a>; <a href="./references#CD013346-bbs2-0293" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al. Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology &amp; Hepatology2016;28:412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a>; <a href="./references#CD013346-bbs2-0141" title="KudoM , UeshimaK , OsakiY , HirookaM , ImaiY , AsoK , et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. Liver Cancer2019;8(4):271-80. ">Kudo 2019</a>; <a href="./references#CD013346-bbs2-0212" title="ParkHJ , JangHY , KimSY , LeeSJ , WonHJ , ByunJH , et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. Journal of Hepatology2020;72(4):718-24. ">Park 2020</a>). By using the bivariate model, the pooled sensitivity was 53% (95% CI 38% to 67%), specificity 96% (95% CI 94% to 97%), LR+ 12.3 (95% CI 7.7 to 19.5), LR‐ 0.5 95% CI 0.36 to 0.68). </p> <p><b>Heterogeneity analysis</b> </p> <p>We investigated heterogeneity while considering studies using US as the index test and found no difference between the prespecified subgroups (<a href="#CD013346-tbl-0006">Table 4</a>). </p> <div class="table" id="CD013346-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Heterogeneity and sensitivity analyses for ultrasonography (US)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (63% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (64% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (77% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.737</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71% (62% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (92% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (60% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (58% to 82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (70% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (92% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.091</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67% (54% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (88% to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (60% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (73% to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.186</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% (45% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (58% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (85% to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (54% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (92% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (62% to 82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (88% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (61% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (89% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (57% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (91% to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (75% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (60% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.088</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% (52% to 77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (91% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (64% to 91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (84% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.379</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55% (41% to 69%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (93% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (64% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (57% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (58% to 91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (79% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% (33% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (83% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.346</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (52% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (82 to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US positivity criteria predefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (63% to 83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (89% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterpretable test results reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (71% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (71% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (64% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>OLT</b> : orthotopic liver transplantation; <b>HCC</b>: hepatocellular carcinoma </p> </div> </div> <p><b>Sensitivity analysis</b> </p> <p>When considering only the 36 studies with a cross‐sectional design, we obtained a pooled sensitivity of 71% (95% CI 62% to 79%) and a specificity of 95% (95% CI 92% to 97%; <a href="#CD013346-tbl-0006">Table 4</a>). </p> <p>When considering only the 25 studies that prespecified the positivity criteria, we obtained a pooled sensitivity of 74% (95% CI 63% to 83%) and a specificity of 93% (95% CI 89% to 96%; <a href="#CD013346-tbl-0006">Table 4</a>). </p> <p>When considering only the three studies reporting uninterpretable results with intention‐to‐diagnose analysis, we obtained a sensitivity of 80% (95% CI 71% to 81%) and a specificity of 76% (95% CI 71% to 81%). </p> <p>When considering the 38 studies published in full text and excluding the two published studies in abstract form, we obtained sensitivity of 72% (95% CI 64% to 80%) and specificity of 94% (95% CI 91% to 96%). </p> </section> </section> <section id="CD013346-sec-0083"> <h5 class="title">Combination of AFP and US</h5> <section id="CD013346-sec-0084"> <h6 class="title">Description of the included studies</h6> <p>Eight studies with 5454 participants provided data assessing the combination of measurement of serum AFP and abdominal US for the diagnosis of HCC. </p> <p>All studies considered positive the combination of the two tests when at least one was positive. The median prevalence of the target disease was 16% (IQR 9% to 17%). The median proportion of participants with liver cirrhosis was 100% (data reported by eight studies: in six studies it was 100%, in one study it was 93%, and in another study it was 53%). The median prevalence of participants with Child‐Pugh class A was 86% (data reported by four studies, IQR 60% to 96%) and the median prevalence of participants with viral aetiology was 84% (six studies, IQR 44% to 88%). The median proportion of resectable HCC was 76% (six studies, IQR 59% to 91%), and the mean diameter was 24 mm (four studies, IQR 18.5 to 31.5 mm). The studies were conducted from 1988 to 2019. Considering study location, three studies were conducted in North and South America, three in Asia, one in Europe, and one in three continents. Seven studies were conducted in the context of a surveillance programme for HCC and two studies in participants with the clinical suspected HCC. </p> <p><a href="#CD013346-fig-0009">Figure 9</a> shows the forest plot of sensitivity and specificity with their 95% CIs, and <a href="./appendices#CD013346-sec-0108">Appendix 6</a> shows a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 ‐ specificity). Considering only the six studies (5,044 participants) which used for AFP a cut‐off value of 20 ng/mL, we performed a meta‐analysis using the bivariate model and we obtained the following pooled estimates: sensitivity 96% (95% CI 88% to 98%), specificity 85% (95% CI 73% to 93%), LR+ 6.5 (95% CI 3.5 to 12.0) and LR‐ 0.05 (95% CI 0.02 to 0.14; (<a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>; <a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>)). </p> <div class="figure" id="CD013346-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plots of sensitivity and specificity of the combination of alpha‐foetoprotein and ultrasound against different reference standards in 8 studies ordered by increasing sensitivity.Rreference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)" data-id="CD013346-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of the combination of alpha‐foetoprotein and ultrasound against different reference standards in 8 studies ordered by increasing sensitivity.Rreference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line) </p> </div> </div> </div> <p>We assessed the diagnostic accuracy for resectable HCC as a secondary objective. We found only two studies with more than 90% of participants with resectable HCC, preventing a meta‐analysis of their results: <a href="./references#CD013346-bbs2-0056" title="ChoiJ , KimGA , HanS , LeeW , ChunS , LimYS . Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.)2019;69(5):1983-94. ">Choi 2019</a> with 203 participants, reported a sensitivity of 89% (95% CI 73% to 97%) and specificity of 83% (95% CI 76% to 88%) and <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a> with 106 participants, reported a sensitivity of 79% (95% CI 54% to 94%) and a specificity of 87% (95% CI 79% to 94%). </p> <p><b>Heterogeneity analysis</b> </p> <p>We investigated heterogeneity while considering studies using the combination of AFP 20 ng/mL and US as the index test and found no difference between some prespecified subgroups: prospective compared to retrospective studies, studies conducted before 2000 compared to those conducted after 2000, studies with HCC prevalence lower than 10% compared to studies with HCC prevalence higher than 10%, studies conducted in surveillance programmes compared to studies conducted in people with suspected HCC. We could not assess the remaining comparisons because of the small number of included studies (<a href="#CD013346-tbl-0007">Table 5</a>). </p> <div class="table" id="CD013346-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Heterogeneity and sensitivity analyses for the combination of alpha‐foetoprotein (AFP) (cut‐off 20 ng/mL) and ultrasonography (US)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (84% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (75% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.578</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (83% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77% (66% to 85%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (44% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (69% to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.703</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (89% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (69% to 95%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (83% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (67% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> <p>90% (77% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (79% to 94%)</p> <p>83% (79% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> <p>82% (81% to 84%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (78% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (76% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (79% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (68% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (78% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (92% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (70% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (84% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (72% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (78% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (86% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (72% to 95%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (79% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> <p>82% (81% to 84%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (83% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (67% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>*§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US positivity criteria predefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (77% to 97%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (79% to 87%)</p> <p>82% (81% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Sparse and missing data. Meta‐analysis not conducted</p> <p>§ Model failed to converge</p> <p><b>OLT</b> : orthotopic liver transplantation; <b>HCC</b> : hepatocellular carcinoma; <b>US</b>: ultrasonography </p> </div> </div> <p><b>Sensitivity analysis</b> </p> <p>We did not perform the sensitivity analyses as all the studies were judged to be at high risk of bias; all the studies were cross‐sectional; no study reported uninterpretable results; all the studies were published as full text, and only two studies reported predefined US positivity criteria (<a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="#CD013346-tbl-0007">Table 5</a>). </p> </section> </section> <section id="CD013346-sec-0085"> <h5 class="title">Comparative analyses</h5> <p>The indirect comparison between the 147 studies with AFP at a cut‐off value of around 20 ng/mL showed an AFP sensitivity of 60% (95% CI 58% to 62%) and specificity of 84% (95% CI 82% to 86%) compared to the 39 studies with US showing a sensitivity of 72% (95% CI 63% to 79%) and specificity of 94% (95% CI 91% to 96%). Both US sensitivity (P = 0.0011) and specificity (P &lt; 0.0001) were higher than those of AFP (<a href="#CD013346-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD013346-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) showing the indirect comparison (between study) of the results of two different index tests, ultrasound (black circles) and alpha‐foetoprotein with a cut‐off value around 20 ng/mL (red diamonds) against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months).The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and AFP cut‐off 20 ng/ml (red circle).”The dotted lines represent the 95% confidence regions." data-id="CD013346-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the indirect comparison (between study) of the results of two different index tests, ultrasound (black circles) and alpha‐foetoprotein with a cut‐off value around 20 ng/mL (red diamonds) against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months). </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and AFP cut‐off 20 ng/ml (red circle).” </p> <p>The dotted lines represent the 95% confidence regions.</p> </div> </div> </div> <p>For the direct comparison between the two tests, 15 studies provided data assessing AFP measurement with a cut‐off value of 20 ng/mL and abdominal US (<a href="./references#CD013346-bbs2-0205" title="OkazakiN , YoshidaT , YoshinoM , MatueH . Screening of patients with chronic liver disease for hepatocellular carcinoma by ultrasonography. Clinical Oncology1984;10:241-6. ">Okazaki 1984</a>; <a href="./references#CD013346-bbs2-0059" title="CottoneM , TurriM , CaltagironeM , MaringhiniA , SciarrinoE , VirdoneR , et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alpha fetoprotein: a prospective study. Hepato-gastroenterology1988;35:101-3. ">Cottone 1988</a>; <a href="./references#CD013346-bbs2-0172" title="MaringhiniA , CottoneM , SciarrinoE , MarcenóMP , La SetaF , FuscoG , et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Digestive Diseases and Sciences1988;33(1):47-51. ">Maringhini 1988</a>; <a href="./references#CD013346-bbs2-0284" title="TremoladaF , BenvegnùL , DragoC , CasarinC , CecchettoA , et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alpha-fetoprotein, ultrasound and fine-needle biopsy. Hepato-gastroenterology1989;36(6):519-21. ">Tremolada 1989</a>; <a href="./references#CD013346-bbs2-0248" title="ShermanM , PeltekianKM , LeeC . Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology (Baltimore, Md.)1995;22(2):432-8. ">Sherman 1995</a>; <a href="./references#CD013346-bbs2-0044" title="ChalasaniN , Horlander JC Sr, SaidA , HoenH , KopeckyKK , Stockberger SM Jr, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. American Journal of Gastroenterology1999;94(10):2988-93. ">Chalasani 1999</a>; <a href="./references#CD013346-bbs2-0097" title="Gambarin-GelwanM , WolfDC , ShapiroR , SchwartzME , MinAD . Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. American Journal of Gastroenterology2000;95(6):1535-8. ">Gambarin‐Gelwan 2000</a>; <a href="./references#CD013346-bbs2-0311" title="WongGL , WongVW , TanGM , IpKI , LaiWK , LiYW , et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver International2008;28(1):79-87. ">Wong 2008</a>; <a href="./references#CD013346-bbs2-0252" title="SingalAG , ConjeevaramHS , VolkML , FuS , FontanaRJ , AskariF , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(5):793-9. ">Singal 2012</a>; <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>; <a href="./references#CD013346-bbs2-0048" title="ChangTS , WuYC , TungSY , WeiKL , HsiehYY , HuangHC , et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. American Journal of Gastroenterology2015;110(6):836-44. ">Chang 2015</a>; <a href="./references#CD013346-bbs2-0290" title="UngtrakulT , MahidolC , Chun-OnP , LaohapandC , SiripongsakunS , WorakitsitisatornA , et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology2016;22(34):7806-12. ">Ungtrakul 2016</a>; <a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>; <a href="./references#CD013346-bbs2-0139" title="KimMN , KimBK , KimSU , ParkJY , AhnbSH , HanbKH , et al. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scandinavian Journal of Gastroenterology2019;54(10):1283-90. ">Kim 2019b</a>; <a href="./references#CD013346-bbs2-0325" title="YangJD , AddissieBD , MaraKC , HarmsenWS , DaiJ , ZhangN , et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiology, Biomarkers &amp; Prevention2019;28(3):531-8. ">Yang 2019</a>). We found that four studies (<a href="./references#CD013346-bbs2-0248" title="ShermanM , PeltekianKM , LeeC . Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology (Baltimore, Md.)1995;22(2):432-8. ">Sherman 1995</a>; <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>; <a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>; <a href="./references#CD013346-bbs2-0325" title="YangJD , AddissieBD , MaraKC , HarmsenWS , DaiJ , ZhangN , et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiology, Biomarkers &amp; Prevention2019;28(3):531-8. ">Yang 2019</a>) reported data obtained in different participants for the two index tests. For this reason, we excluded them from the direct comparison analysis. Thus, we included 11 studies with 6674 participants allowing a direct comparison (<a href="#CD013346-fig-0011">Figure 11</a>). By using the bivariate model, we obtained the following pooled estimates: for AFP (cut‐off value 20 ng/mL), sensitivity 64% (95% CI 56% to 71%) and specificity 89% (95% CI 79% to 94%); for US, sensitivity 81% (95% CI 66% to 90%) and specificity 92% (95% CI 83% to 97%). The sensitivity of US was higher (P = 0.0044; relative sensitivity 1.27, 95% CI 1.06 to 1.49) while the specificities did not differ (P = 0.3861; relative specificity 1.04, 95% CI 0.95 to 1.12). </p> <div class="figure" id="CD013346-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and ultrasound (red diamonds)in the same participants against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months).The solid circles represent the summary estimates of sensitivity and specificity for AFP, with cut‐off around 20 ng/ml (black circle) and for US, for direct comparison (red circle).”The dotted lines represent the 95% confidence regions.." data-id="CD013346-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and ultrasound (red diamonds)in the same participants against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months). </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for AFP, with cut‐off around 20 ng/ml (black circle) and for US, for direct comparison (red circle).” </p> <p>The dotted lines represent the 95% confidence regions.</p> <p>.</p> </div> </div> </div> <p>Seven studies provided data assessing either US or the combination of US and AFP with a cut‐off 20 ng/mL. After excluding the <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a> study which reported data obtained in different participants, six studies with 5044 participants allowed a direct comparison (<a href="#CD013346-fig-0012">Figure 12</a>). By using the bivariate model, we obtained for US a sensitivity of 76% (95% CI 56% to 89%) and a specificity of 93% (95% CI 80% to 98%); for the combination of US and AFP, a sensitivity of 96% (95% CI 88% to 98%) and a specificity of 85% (95% CI 73% to 92%). The sensitivity of the combination of US and AFP was higher (P = 0.0141; relative sensitivity 1.28, 95% CI 1.03 to 1.53) while the specificity did not differ (P = 0.1024; relative specificity 0.94, 95% CI 0.87 to 1.01) compared with US alone. </p> <div class="figure" id="CD013346-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, ultrasound (black circles) and the combination of alpha‐foetoprotein with a cut of value around 20 ng/mL and ultrasound (red diamonds) in the same participants against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation,the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and US + AFP cut‐off 20 ng/ml (red circle).The dotted lines represent the 95% confidence regions." data-id="CD013346-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, ultrasound (black circles) and the combination of alpha‐foetoprotein with a cut of value around 20 ng/mL and ultrasound (red diamonds) in the same participants against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation,the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and US + AFP cut‐off 20 ng/ml (red circle). </p> <p>The dotted lines represent the 95% confidence regions.</p> </div> </div> </div> </section> <section id="CD013346-sec-0086"> <h5 class="title">Summaryof findings tables</h5> <p>The main results are shown in the <a href="./full#CD013346-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013346-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013346-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013346-sec-0087"></div> <section id="CD013346-sec-0088"> <h3 class="title" id="CD013346-sec-0088">Summary of main results</h3> <p>This review aimed to assess the diagnostic accuracy of abdominal ultrasound (US) and alpha‐foetoprotein (AFP), alone or in combination, for the diagnosis of hepatocellular carcinoma (HCC) of any size and at any stage in people with chronic liver disease, either in a surveillance programme or in a clinical setting. The main results are shown in the <a href="./full#CD013346-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013346-tbl-0002">summary of findings Table 2</a> tables. </p> <p>We included 373 studies: 326 studies assessed AFP as the index test in 144,570 participants; 39 studies assessed abdominal US in 18,792 participants; and eight studies assessed both AFP and abdominal US as the index tests in 5454 participants. </p> <p>We judged only one study (US as the index test) to be at low risk of bias for all four QUADAS‐2 domains (<a href="./references#CD013346-bbs2-0030" title="BennettGL , KrinskyGA , AbitbolRJ , KimSY , TheiseND , TepermanLW . Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis:Correlation of pre transplantation sonography and liver explant pathology in 200 patients. AJR. American Journal of Roentgenology2002;179:75-80. ">Bennett 2002</a>); all the remaining studies were considered to be at high or unclear risk of bias in at least one domain. We also judged most studies (323/373) to be at high concern for the applicability of the results, mainly because of the patient selection domain, as only people with viral aetiology or decompensated liver disease were included, or participants were selected according to volume or other characteristics of the target disease, and because of the reference standard domain, as to confirm the presence of HCC, pathological examination of explanted liver, or of surgical specimen, or necroscopy, or technologies no longer in use, were required. </p> <p>We summarised the main results of analyses in the <a href="./full#CD013346-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013346-tbl-0002">summary of findings Table 2</a>. We considered the following consequences of test results: people with true‐positive results, i.e. with HCC and positive test results, will receive appropriate further testing and possibly treatment; people with true‐negative results, i.e. without HCC and negative test results, will appropriately avoid further testing; people with false‐negative results, i.e. with HCC and negative test results, are misdiagnosed and will not receive the appropriate treatment; people with false‐positive results, i.e. without HCC and positive test results, will undergo inappropriately further testing with computed tomography (CT), contrast‐enhanced ultrasound (CEUS), magnetic resonance imaging (MRI), or biopsy. </p> <p>The prevalence of HCC varied widely, from 1% to 82%, according to the study design and the different settings. For exemplification, we considered in the 'Summary of findings' tables two different populations: a population at low risk of HCC, with an HCC prevalence of 5%, a value close to that reported by most epidemiological studies (<a href="./references#CD013346-bbs2-0607" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gatroenterology2009;136(1):138-48.">Lok 2009</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0587" title="FornerA , ReigM , BruixJ . Hepatocellular carcinoma. Lancet2018;391:1301-14.">Forner 2018</a>); a population at high risk of HCC, with a prevalence of 30%, that is the median of the prevalence in the included cross‐sectional studies conducted in clinical cohorts. </p> <section id="CD013346-sec-0089"> <h4 class="title">Alpha‐foetoprotein (AFP)</h4> <p>There was a wide variation in the used cut‐off values in the studies with AFP as the index test, and, therefore, we performed a meta‐analysis with the hierarchical summary ROC model (HSROC) (<a href="#CD013346-fig-0003">Figure 3</a>). There was a considerable heterogeneity in the accuracy estimates, which could in some degree be attributable to the different cut‐off values. In order to obtain a pooled estimate of the sensitivity and the specificity, we chose the two most used cut‐off values: around 20 ng/mL reported in 147 of 326 studies, and 200 ng/mL reported in 56 studies. </p> </section> <section id="CD013346-sec-0090"> <h4 class="title">AFP cut‐off around 20 ng/mL</h4> <p>For AFP with a cut‐off of around 20 ng/mL, performing the meta‐analysis with the bivariate model, we obtained the following pooled estimates: sensitivity of 60% (95% CI 58% to 62%) and specificity of 84% (95% CI 82% to 86%). Considering a hypothetical cohort of 1000 people with an HCC prevalence of 5%, we can expect 20 false‐negative and 148 false‐positive results; with a prevalence of 30%, we can expect 121 false‐negative and 109 false‐positive results (<a href="./full#CD013346-tbl-0001">summary of findings Table 1</a>). </p> <p>These results were also consistent with those obtained in a sensitivity analysis considering the studies with a cross‐sectional design alone. We found the setting of the studies as a possible source of heterogeneity: we found different results in studies with enrolment from surveillance programmes compared to studies with enrolment from clinical series. We observed some heterogeneity of accuracy estimates between studies (sensitivity, IQR from 53% to 67%; specificity, IQR from 76% to 90%). Altogether, the heterogeneity of the results remained unexplained despite the exploration of many other possible sources. We did not find any difference between studies with cross‐sectional and case‐control design. Moreover, the results seem consistent in different geographical areas, along the time, according to HCC prevalence and volume, and according to viral or non viral aetiology and severity of the underlying chronic liver disease. The pooled estimates are quite precise with narrow 95% CIs, but all the studies were at high risk of bias and at high concern for applicability, and with a wide inconsistency that could not be explained by the investigation of potential sources. We judged the certainty of evidence as very low. </p> </section> <section id="CD013346-sec-0091"> <h4 class="title">AFP cut‐off value of 200 ng/mL</h4> <p>For the 56 studies on AFP with a cut‐off value of 200 ng/mL, performing the meta‐analysis with bivariate model, we obtained sensitivity of 36% (95% CI 31% to 41%) and specificity of 99% (95% CI 98% to 99%). Considering a hypothetical cohort of 1000 people with a HCC prevalence of 5%, we can expect 32 false‐negative and 10 false‐positive results; with a prevalence of 30%, we can expect 195 false‐negative and 7 false‐positive results (<a href="./full#CD013346-tbl-0001">summary of findings Table 1</a>). These results were consistent also in a sensitivity analysis of the studies with cross‐sectional design alone. We observed some heterogeneity of accuracy estimates between studies (sensitivity, IQR, 23% to 50%; specificity, IQR 97% to 100%). As possible sources of heterogeneity, we found geographical location (studies conducted in different continents) and severity of the underlying liver disease, according to Child‐Pugh classification (<a href="#CD013346-tbl-0005">Table 3</a>). The pooled estimates are quite precise with narrow 95% CIs, but all studies were at high risk of bias and at high concern for applicability, and with a wide inconsistency that could not be explained by the investigation of potential sources. We judged the certainty of evidence as very low. </p> <section id="CD013346-sec-0092"> <h5 class="title">Abdominal ultrasound</h5> <p>For the 39 studies using US as the index test, performing the meta‐analysis with bivariate model, we obtained the following pooled estimates: sensitivity of 72% (95% CI 63% to 79%) and specificity of 94% (95% CI 91% to 96%). Considering a hypothetical cohort of 1000 people with an HCC prevalence of 5%, we can expect 2 false‐negative and 143 false‐positive results; with a prevalence of 30%, we can expect 143 false‐negative and 42 false‐positive results (<a href="./full#CD013346-tbl-0001">summary of findings Table 1</a>). We observed some heterogeneity of accuracy estimates between studies (sensitivity, IQR 44% to 89%; specificity, IQR 86% to 96%). Our investigation of the potential sources cannot explain this inconsistency of the results. Most studies are at high risk of bias and many at high concern for applicability. The pooled estimates of accuracy have narrow 95% Cl. We judged the certainty of evidence as very low. </p> </section> <section id="CD013346-sec-0093"> <h5 class="title">Combination of AFP and abdominal ultrasound</h5> <p>For the six studies, using a combination of AFP with cut‐off value 20 ng/mL and US as index test, the meta‐analysis with the bivariate model produced the following pooled estimates: sensitivity of 96% (95% CI 88% to 98%) and specificity of 85% (95% CI 73% to 93%). Considering a hypothetical cohort of 1000 people with a HCC prevalence of 5%, we can expect 2 false‐negative and 143 false‐positive results; with a prevalence of 30%, we can expect 2 false‐negative and 105 false‐positive results (<a href="./full#CD013346-tbl-0001">summary of findings Table 1</a>). All studies are at high risk of bias and many at high concern for applicability. We did not find a considerable inconsistency of the results and imprecision of the estimates with wide confidence intervals 95% Cl. We judged the certainty of evidence as low. </p> </section> <section id="CD013346-sec-0094"> <h5 class="title">Comparisons</h5> <p>We compared the results of the two index tests: AFP and US. We performed a direct (within‐study) comparison in 11 studies using US and AFP with a cut‐off value of around 20 ng/mL and showing a higher sensitivity of US with similar specificities (<a href="#CD013346-fig-0011">Figure 11</a>). An indirect comparison between 147 AFP studies, with a cut‐off value of around 20 ng/mL, and 39 US studies showed a higher sensitivity and specificity of US (<a href="#CD013346-fig-0010">Figure 10</a>). The direct comparison considering only the six studies, reporting both US and the combination of AFP (cut‐off 20 ng/mL) as index test and US performed in the same participants, showed a higher sensitivity of the combination of AFP and US (relative sensitivity 1.28, 95% CI 1.03 to 1.53, P = 0.0141), while the specificities did not differ (relative specificity 0.94, 95% CI 0.87 to 1.01; <a href="#CD013346-fig-0012">Figure 12</a>). All studies were at high risk of bias and many at high concern for applicability. We judged the certainty of evidence as low (<a href="./full#CD013346-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> </section> <section id="CD013346-sec-0095"> <h3 class="title" id="CD013346-sec-0095">Strengths and weaknesses of the review</h3> <p><b>Strengths and weaknesses of included studies</b> </p> <p>Overall, the included studies cover a vast time span and a wide geographical distribution including areas with high and low prevalence of chronic liver disease and HCC. </p> <p>We found more studies using AFP (n = 326) than using US (n = 39), or the combination of AFP and US (n = 8) as the index test. As we anticipated, many studies with biomarkers were conducted with a case‐control design, and in order to improve the completeness of our review, we included studies that compared people with known HCC to matched control. The large number of studies allowed us to obtain precise summary estimates of sensitivity and specificity with narrow confidence intervals. On the other hand, we found only 11 studies providing data for a direct (within study) comparison of AFP and US. </p> <p>An overall quality assessment of the studies showed some common methodological weaknesses. We considered only one study to be at low risk of bias (<a href="./references#CD013346-bbs2-0030" title="BennettGL , KrinskyGA , AbitbolRJ , KimSY , TheiseND , TepermanLW . Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis:Correlation of pre transplantation sonography and liver explant pathology in 200 patients. AJR. American Journal of Roentgenology2002;179:75-80. ">Bennett 2002</a>). In most studies with AFP as the index test, the design was case‐control and the risk of bias was high for patient selection. Furthermore, different cut‐off values were used, ranging from 5 ng/mL to 1000 ng/mL, and these were rarely predefined. The choice of the reference standard was also a major concern for all studies, either with AFP or US, or the combination of AFP and US as index test. The most used reference standard was CT or MRI, or their combination (as also recommended by most clinical guidelines; (<a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>; <a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>)), but these tests cannot be regarded as absolutely accurate. Another choice of a reference standard was the histology of focal lesion, which is highly specific, but not sensitive, especially for small lesions, and cannot be obtained in the participants with a negative index test. Lastly, another reference standard is the pathology of the explanted liver which is possible only in studies conducted on participants with advanced and decompensated liver disease on a waiting list for transplantation which does not match the review question. In some studies, an AFP value, higher than 200 ng/mL, 400 ng/mL, or 500 ng/mL was one of the criteria for the reference standard. Moreover, in case‐control studies, it was often unclear how the target disease was excluded in control participants. Reporting the time interval between the index test and the reference standard was very rare, and often participants underwent different reference standards according to the results of the index test. Furthermore, US is also considered associated with frequent technical failure and with uninterpretable results: interferences due to extrinsic factors such as interposed bowel, ribs, lung, or ascites, as well as patient factors such as obesity or inability to comply with breathing instructions, severe steatosis or severe parenchymal heterogeneity from advanced cirrhosis may impair visualisation of the liver (<a href="./references#CD013346-bbs2-0619" title="RodgersSK , FetzerDT , GabrielH , SeowJH , ChoiHH , MaturenKE , et al. Role of US LI-RADS in the LI-RADS algorithm. Radiographics2019;39:690-708.">Rodgers 2019</a>). Up to 14% of US examination were retrospectively judged as inadequate and only 66.5% as definitely adequate in a study of US quality in a HCC surveillance programme in people with liver cirrhosis (<a href="./references#CD013346-bbs2-0629" title="SimmonsO , FetzerDT , YokooT , MarreroJA , YoppA , KonoY , et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2017;45(1):169-77.">Simmons 2017</a>). We found only three studies that addressed this problem reporting the number of uninterpretable results. Not reporting these technical failures of US examination and excluding them from analyses could have produced an overestimation of test accuracy. </p> <p>Using QUADAS‐2, we judged more than 85% of the included studies at high concern for applicability. The case‐control design, adopted in most AFP studies, results in an artefactual mixing of affected and non‐affected participants which impairs applicability. However, even in cross‐sectional studies, as were most US and combination of AFP and US studies, the inclusion/exclusion criteria and different settings make the included participants different from those targeted by the review question. On the contrary, we judged at low concern most studies for the other two domains, i.e. index test and reference standard. </p> <p>Finally, many studies did not report all the covariates we planned to assess as possible source of heterogeneity, and this might have impaired both their and our analyses. </p> <p><b>Strengths and weaknesses of the review process</b> </p> <p><b>Limitations of the search strategy</b> </p> <p>Our search strategy allowed us to obtain a large number of studies that were conducted in various countries, showing a widespread implementation globally of the index tests, and confirming the clinical relevance of the review question. In order to improve the completeness of our review, we planned to include even studies with case‐control design that are considered to be at high risk of bias due to inflated accuracy estimates and could have been excluded. Most studies on biomarkers, such as AFP, are conducted with case‐control design and indeed, almost 80% of the included AFP studies were case‐control studies. Interestingly, their results were not different from those obtained by cross‐sectional studies. Furthermore, we included many studies in which AFP was not used as the index test but as the comparator to some other biomarker, and this choice might arguably make publication bias less probable. We identified seven studies through manual searching of the references of the included studies or of previous reviews, and we are confident that we have included most, if not all, of the includable published studies. We applied no language restrictions in the inclusion criteria, and we retrieved 20 full‐text studies published in non‐English languages, of which we included six studies. </p> <p><b>Quality assessment and data extraction</b> </p> <p>We considered our attempts to reduce subjectivity in our judgments and to minimise errors and miscalculations in data extraction as a strength of this review. According to the protocol plan, two review authors independently assessed the risk of bias of included studies and applicability of their results, using QUADAS‐2, and completed the data extraction for each included study using a proper form. In case of disagreement, we reached consensus through discussion. Disagreement was more frequent for the assessment of two QUADAS‐2 domains: patient selection (19 studies) and reference standard (15 studies). For data extraction, most of the discordances were due to simple miscalculations or typos and easily solved. For 27 studies a discussion was needed. The agreement obtained through discussion by two review authors was further discussed and approved by a third review author. Then the same authors assessed the certainty of evidence using the GRADE approach and the level of agreement was very high. </p> <p><b>Limitations in the review analyses</b> </p> <p>Despite the large number of included studies and participants, and the consequent precision of accuracy estimates, the results of included studies were not consistent. The use of different cut‐off values and different setting (surveillance programme compared to clinical series) could explain heterogeneity only in part. Considering only studies with the same AFP cut‐off values, the most frequent cut‐off values of 20 ng/mL and 200 ng/mL allowed obtaining more consistent estimates. </p> <p>In studies with AFP with a cut‐off of 20 ng/mL only, we found that study setting was another source of heterogeneity: studies conducted in a surveillance programme compared to those conducted in a clinical setting showed different pooled estimates, with a lower sensitivity and higher specificity in the former. We expected that studies conducted in a surveillance programme would obtain more consistent results: inclusion and exclusion criteria were clear and standardised, such as the index test, reference standard, and timing, whereas, in a clinical setting more variability was expected as participants may have different concurrent disease, different severity of the underlying chronic liver disease, and different stage of the detected HCC. Arguably, in a surveillance programme the underlying liver disease is less severe, and HCCs are smaller. Despite these considerations, we did not plan a separate analysis for the two settings as they are not so clearly distinct in the actual clinical practice (<a href="./references#CD013346-bbs2-0615" title="PoustchiH , FarrellGC , StrasserSI , LeeAU , McCaughanGW , GeorgeJ . Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Hepatology (Baltimore, Md.)2011;54:1998-2004.">Poustchi 2011</a>; <a href="./references#CD013346-bbs2-0587" title="FornerA , ReigM , BruixJ . Hepatocellular carcinoma. Lancet2018;391:1301-14.">Forner 2018</a>). The two index tests, particularly US, are part of the routine evaluation of people with liver disease; HCC, the target disease, induces no symptom and is usually asymptomatic, thus the clinical suspect of HCC is based only on the presence of a chronic advance liver disease. On the other hand, we found no difference according to the study settings in studies with AFP cut‐off value of 200 ng/mL, or with US. </p> <p>As 80% of hepatocellular carcinoma occurrences occur in sub‐Saharan Africa and eastern Asia, we expected that study geographical location could be a source of heterogeneity (<a href="./references#CD013346-bbs2-0570" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). The sensitivity was different in studies conducted across continents in studies with AFP cut‐off of 200 mg/mL. The severity of the underlying liver disease, as expressed by the percentage of participants with Child‐Pugh class A, could also provide explanation of the heterogeneity of results. The sensitivity was lower in studies with AFP cut‐off of 200 ng/mL and including more than 50% of patients with Chid‐Pugh class A, i.e. participants with less severe liver disease. </p> <p>Despite the availability of an adequate number of studies, we were unable to demonstrate any role of aetiology of the underlying chronic liver disease and of the HCC characteristics (volume, resectability). Most studies, conducted either in a surveillance programme or in a clinical setting included inconsistent mixture of participants at different risk of HCC, as shown by the large variability of the prevalence, and we were unable to show the role of the individual characteristics of participants. We could investigate only characteristics that could be assessed at a study level whereas patients' factors or HCC characteristics can be assessed only by aggregate statistics with the inherent risk of ecological bias. Thus, some important relationship such as that with the HCC volume could have been missed. In addition, many of the included studies did not report data on the covariates of our interest. Also, we could not evaluate variability associated to test interpretation, particularly for US which is considered dependent on a subjective judgment. We checked the presence of a definition of US positivity criteria in single studies but not their stringency, apart from their subjective interpretation. We were also unable to assess the effect of uninterpretable results which should be relevant for US due to frequent technical failures. We found only two studies reporting the number of uninterpretable results and could not conduct the planned analysis according to the intention‐to‐diagnose principle. Moreover, we cannot exclude that most of the studies did not report uninterpretable results and excluded them from analyses, thus inflating the accuracy estimates. </p> <p>In any case, the sensitivity analyses show that the obtained results are arguably robust, with no variation, after excluding studies published in abstract form or studies with case‐control design. As we conducted the analyses of AFP studies using the two most frequent cut‐off values of 20 ng/mL and 200 ng/mL, we considered unnecessary to conduct the planned analysis excluding studies without a predefinition of a cut‐off value. </p> <p><b>Within‐ and between‐study comparisons</b> </p> <p>In order to assess any difference in the accuracy of the three index tests (AFP, US, and the combination of AFP and US) ,we planned and performed a direct (or within‐study) comparison. After the exclusion of the four studies that reported data for two or three index tests obtained in different numbers of participants (<a href="./references#CD013346-bbs2-0248" title="ShermanM , PeltekianKM , LeeC . Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology (Baltimore, Md.)1995;22(2):432-8. ">Sherman 1995</a>; <a href="./references#CD013346-bbs2-0226" title="RaffE , KakatiDD , ShoreibahMG , BloomerJR , SingalAK . CT and MRI scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology2014;146(5 Suppl 1):S-606. ">Raff 2014</a>; <a href="./references#CD013346-bbs2-0018" title="AtiqO , TiroJ , YoppAC , MufflerA , MarreroJA , ParikhND , et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology (Baltimore, Md.)2017;65(4):1196-205. ">Atiq 2017</a>; <a href="./references#CD013346-bbs2-0325" title="YangJD , AddissieBD , MaraKC , HarmsenWS , DaiJ , ZhangN , et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiology, Biomarkers &amp; Prevention2019;28(3):531-8. ">Yang 2019</a>), we could do a direct comparison with 11 primary studies with AFP and US, and with six studieswith US, and a combination of AFP and US. The US sensitivity was higher than that of AFP at a cut‐off of 20 ng/mL, with comparable specificity. Also, with the combination of AFP (cut‐off 20 ng/mL) and US, the sensitivity increased, in comparison to US alone, from 74% to 93% with comparable specificity. These results were confirmed by the indirect (between‐study) comparisons which were possible in a greater number of studies (146 with AFP and 39 with US). This between‐study comparison, including a greater number of studies, and hence with more power to detect any difference and with more precise results, has a high risk of confounding due to differences in population characteristics, reference standards, and study design. </p> <p><b>Comparison with previous research</b> </p> <p>We found seven reviews on the same topic (<a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD013346-bbs2-0632" title="TateishiR , YoshidaH , MatsuyamaY , MineN , KondoY , OmataM . Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International2008;2:17-30.">Tateishi 2008</a>; <a href="./references#CD013346-bbs2-0630" title="SingalA , VolkML , WaljeeA , SalgiaR , HigginsP , RogersMA , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2009;30:37-47.">Singal 2009</a>; <a href="./references#CD013346-bbs2-0596" title="KansagaraD , PapakJ , PashaAS , O'NeilM , FreemanM , RelevoR , et al. Screening for hepatocellular carcinoma in chronic liver disease. Annals of Internal Medicine2014;161:261-9.">Kansagara 2014</a>; <a href="./references#CD013346-bbs2-0631" title="SingalAG , PillaiA , TiroJ . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Medicine2014;11:e1001624.">Singal 2014</a>; <a href="./references#CD013346-bbs2-0576" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinsburgA , et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>; <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>). Two of these compared imaging techniques for the diagnosis of HCC (<a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD013346-bbs2-0576" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinsburgA , et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>), one assessed only AFP (<a href="./references#CD013346-bbs2-0632" title="TateishiR , YoshidaH , MatsuyamaY , MineN , KondoY , OmataM . Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International2008;2:17-30.">Tateishi 2008</a>), and four reviews focused mainly on the effectiveness of surveillance programmes with US and AFP (<a href="./references#CD013346-bbs2-0630" title="SingalA , VolkML , WaljeeA , SalgiaR , HigginsP , RogersMA , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology &amp; Therapeutics2009;30:37-47.">Singal 2009</a>; <a href="./references#CD013346-bbs2-0596" title="KansagaraD , PapakJ , PashaAS , O'NeilM , FreemanM , RelevoR , et al. Screening for hepatocellular carcinoma in chronic liver disease. Annals of Internal Medicine2014;161:261-9.">Kansagara 2014</a>; <a href="./references#CD013346-bbs2-0631" title="SingalAG , PillaiA , TiroJ . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Medicine2014;11:e1001624.">Singal 2014</a>; <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>). With our search, we could include many more studies for each index test, and differently from the other reviews, we explored the accuracy of AFP, US, and the combination of AFP and US in the clinical pathway as the first diagnostic step, either in clinical setting or surveillance programme. Due to differences in the methodologic approach, in the inclusion/exclusion criteria, and in the statistical analyses, the results are not comparable to each other and to our results. <a href="./references#CD013346-bbs2-0578" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a> reports the results from 14 studies published before January 2005, and the summary estimate of US sensitivity was 60% and specificity 97%. Both <a href="./references#CD013346-bbs2-0576" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinsburgA , et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a> and <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>, pooling the results of more recent 15 studies, found a US sensitivity higher than 75% and specificity higher than 90%, more similar to our findings. According to <a href="./references#CD013346-bbs2-0633" title="TzartzevaK , ObiJ , RichNE , ParikhND , MarreroJA , YoppA , et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology2018;154:1706-18.">Tzartzeva 2018</a>, the accuracy of combining US and AFP improves the diagnostic accuracy with a sensitivity of 97%, but for the detection of early HCC it remains close to 60%. </p> </section> <section id="CD013346-sec-0096"> <h3 class="title" id="CD013346-sec-0096">Applicability of findings to the review question</h3> <p>The review question has broad inclusion criteria, and the consequent large heterogeneity of the results allows exploration of variation in accuracy across various settings, different patient groups or variations in index test, and reference standard application. Using the QUADAS‐2 tool, we judged many studies at high concern for applicability in the participant selection domain. In fact, most AFP studies (77%) were case‐control studies with an artefactual mixing of affected and non‐affected participants. However, even in cross‐sectional studies, the prevalence of the target disease ranged from 1% to 82%, as consequences of different settings and variable inclusion criteria often did not match the review question. On the other hand, we judged all studies to be at low concern for applicability in the index test domain. For the reference standard domain, we judged the studies using as reference standard the pathology of the explanted liver to be at high concern. This reference standard, even if perfectly accurate, cannot match the review question as it is applicable only to participants in a waiting list for a liver transplantation. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013346-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram  Date of search: 5 June 2020" data-id="CD013346-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram <br/>Date of search: 5 June 2020 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD013346-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing in 326 studies alpha‐foetoprotein serum measurement with any cut‐off value and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months." data-id="CD013346-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing in 326 studies alpha‐foetoprotein serum measurement with any cut‐off value and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 20 ng/mL against different reference standards in 147 studies ordered by study design, setting and increasing HCC prevalence. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD013346-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 20 ng/mL against different reference standards in 147 studies ordered by study design, setting and increasing HCC prevalence. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and alpha‐foetoprotein with a cut‐off value around 200 ng/mL (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for AFP cut‐off around 20 ng/ml (black circle) and AFP cut off 200 ng/ml (red circle).The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and alpha‐foetoprotein with a cut‐off value around 200 ng/mL (red diamonds) against the same reference standards.<br/>Reference standards were: the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for AFP cut‐off around 20 ng/ml (black circle) and AFP cut off 200 ng/ml (red circle). </p> <p>The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing the results of studies conducted in different settings, surveillance programs (black circles) and clinical setting (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for surveillance setting (black circle) and clinical suspect setting (red circle).The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing the results of studies conducted in different settings, surveillance programs (black circles) and clinical setting (red diamonds) against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for surveillance setting (black circle) and clinical suspect setting (red circle). </p> <p>The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of ultrasound against different reference standards.in 39 studies. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).The individual studies are ordered by study design (cross‐sectional or case‐control), study setting (clinical setting or surveillance program) and increasing sensitivity." data-id="CD013346-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of ultrasound against different reference standards.in 39 studies. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).The individual studies are ordered by study design (cross‐sectional or case‐control), study setting (clinical setting or surveillance program) and increasing sensitivity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing, in 39 studies, ultrasound and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circle represents the summary estimate of sensitivity and specificity.The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions." data-id="CD013346-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing, in 39 studies, ultrasound and different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circle represents the summary estimate of sensitivity and specificity.The dotted lines represent the 95% confidence regions. The dashed lines represent the 95% prediction regions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of the combination of alpha‐foetoprotein and ultrasound against different reference standards in 8 studies ordered by increasing sensitivity.Rreference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)" data-id="CD013346-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of the combination of alpha‐foetoprotein and ultrasound against different reference standards in 8 studies ordered by increasing sensitivity.Rreference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) showing the indirect comparison (between study) of the results of two different index tests, ultrasound (black circles) and alpha‐foetoprotein with a cut‐off value around 20 ng/mL (red diamonds) against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months).The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and AFP cut‐off 20 ng/ml (red circle).”The dotted lines represent the 95% confidence regions." data-id="CD013346-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the indirect comparison (between study) of the results of two different index tests, ultrasound (black circles) and alpha‐foetoprotein with a cut‐off value around 20 ng/mL (red diamonds) against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months). </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and AFP cut‐off 20 ng/ml (red circle).” </p> <p>The dotted lines represent the 95% confidence regions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and ultrasound (red diamonds)in the same participants against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months).The solid circles represent the summary estimates of sensitivity and specificity for AFP, with cut‐off around 20 ng/ml (black circle) and for US, for direct comparison (red circle).”The dotted lines represent the 95% confidence regions.." data-id="CD013346-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, alpha‐foetoprotein with a cut‐off value around 20 ng/mL (black circles) and ultrasound (red diamonds)in the same participants against the same reference standards (the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months). </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for AFP, with cut‐off around 20 ng/ml (black circle) and for US, for direct comparison (red circle).” </p> <p>The dotted lines represent the 95% confidence regions.</p> <p>.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, ultrasound (black circles) and the combination of alpha‐foetoprotein with a cut of value around 20 ng/mL and ultrasound (red diamonds) in the same participants against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation,the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months.The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and US + AFP cut‐off 20 ng/ml (red circle).The dotted lines represent the 95% confidence regions." data-id="CD013346-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) showing the direct comparison (within study) of the results of two different index tests, ultrasound (black circles) and the combination of alpha‐foetoprotein with a cut of value around 20 ng/mL and ultrasound (red diamonds) in the same participants against the same reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation,the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> <p>The solid circles represent the summary estimates of sensitivity and specificity for ultrasound (black circle) and US + AFP cut‐off 20 ng/ml (red circle). </p> <p>The dotted lines represent the 95% confidence regions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD013346-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/appendices#CD013346-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of alpha‐fetoprotein with any cut‐off value against different reference standards in 326 studies ordered by increasing sensitivity. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD013346-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of alpha‐fetoprotein with any cut‐off value against different reference standards in 326 studies ordered by increasing sensitivity. Reference standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/appendices#CD013346-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 200 ng/mL.against different reference standards in 56 studies ordered by increasing sensitivity. Referencev standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)." data-id="CD013346-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-15.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of alpha‐foetoprotein with a cut‐off value around 200 ng/mL.against different reference standards in 56 studies ordered by increasing sensitivity. Referencev standards were: the pathology of the explanted liver in case of transplantation.;the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/appendices#CD013346-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing in 8 studies the combination of alpha‐foetoprotein and ultrasound against different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months." data-id="CD013346-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-16.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing in 8 studies the combination of alpha‐foetoprotein and ultrasound against different reference standards. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months, typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/appendices#CD013346-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-FIG-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-001" target="_blank"><b></b></a></p> </div><img alt="Alpha‐foetoprotein" data-id="CD013346-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-001.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-001.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>Alpha‐foetoprotein</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-002" target="_blank"><b></b></a></p> </div><img alt="Ultrasound" data-id="CD013346-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-002.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-002.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Ultrasound</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-003" target="_blank"><b></b></a></p> </div><img alt="US + AFP" data-id="CD013346-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-003.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-003.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>US + AFP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-004" target="_blank"><b></b></a></p> </div><img alt="AFP cut‐off around 20 ng/mL" data-id="CD013346-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-004.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-004.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>AFP cut‐off around 20 ng/mL</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-005" target="_blank"><b></b></a></p> </div><img alt="AFP cut‐off around 200 ng/mL" data-id="CD013346-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-005.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-005.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>AFP cut‐off around 200 ng/mL</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-006" target="_blank"><b></b></a></p> </div><img alt="US + AFP cut‐off 20 ng/mL" data-id="CD013346-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-006.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-006.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>US + AFP cut‐off 20 ng/mL</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013346-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/urn:x-wiley:14651858:media:CD013346:CD013346-TST-007" target="_blank"><b></b></a></p> </div><img alt="US for direct comparison AFP 20 ng/mL" data-id="CD013346-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-007.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_t/tCD013346-TST-007.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>US for direct comparison AFP 20 ng/mL</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/media/CDSR/CD013346/image_n/nCD013346-TST-007.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013346-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">'Summary of findings' table: diagnostic accuracy of AFP, US, and combination of AFP and US for the diagnosis of HCC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question</b>: what is the diagnostic accuracy of alpha‐foetoprotein (AFP), abdominal ultrasound (US), or of the combination of AFP and abdominal US for the diagnosis of hepatocellular carcinoma (HCC) in adults with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting</b>: clinical setting (secondary or tertiary care setting) or surveillance programs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design</b>: prospective and retrospective cross‐sectional and case‐control studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index tests</b> </p> <p>Serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL</p> <p>Serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 200 ng/mL</p> <p>Abdominal ultrasound (US)</p> <p>Combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound (US) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition</b>: HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b>: </p> <p>the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up period of at least six months to exclude the presence of focal lesions non detected by the index test and synchronous lesions from the parenchyma surrounding the resected or biopsied area; </p> <p>typical characteristics on cross‐sectional multiphasic contrast computer tomography (CT) or magnetic resonance imaging (MRI), with a follow‐up period of at least six months in order to allow the confirmation of an initial negative result on CT or on MRI. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence ‐ Risk of bias/Applicability</b> </p> <p><b>Index test</b>: serum alpha‐foetoprotein (AFP) measurement cut‐off value 20 ng/mL </p> <p>‐ Participant selection: high/unclear risk of bias 141 studies (96%), high concern 115 studies (78%) </p> <p>‐ Index tests: high/unclear risk of bias in 73 studies (50%) high concern: no study</p> <p>‐ Reference standard: high/unclear risk of bias in 105 studies (71%) high concern 33 studies (22%) </p> <p>‐ Flow and timing: high risk of bias in 143 studies (97%)</p> <p><b>Index test</b>: serum alpha‐foetoprotein (AFP) measurement cut‐off value 200 ng/mL </p> <p>‐ Participant selection: high/unclear risk of bias 48 studies (86%), high concern 47(84%) </p> <p>‐ Index tests: high/unclear risk of bias in 54 studies (96%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 39 studies (70%) high concern 13 studies (23%) </p> <p>‐ Flow and timing: high risk of bias in 55 studies (98%)</p> <p><b>Index test</b>: abdominal ultrasound </p> <p>‐ Participant selection: high/unclear risk of bias in 23 studies (59%) high concern 22 studies (56%) </p> <p>‐ Index tests: high/unclear risk of bias in 15 studies (38%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 27 studies (69%) high concern 13 studies (33%) </p> <p>‐ Flow and timing: high risk of bias in 27 studies (TN) (69%)</p> <p><b>Index test</b>: combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound </p> <p>‐ Participant selection: high/unclear risk of bias in 2 studies (33%) high concern 2 studies (33%) </p> <p>‐ Index tests: high/unclear risk of bias in 2 studies (33%) high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 4 studies (67%) high concern one study (17%) </p> <p>‐ Flow and timing: high risk of bias in 6 studies (100%)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Findings</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Implications in a hypothetical cohort of 1000 people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Index test</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies (participants</b>) </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed prevalence of hepatocellular carcinoma (HCC)<sup>a</sup> </b> </p> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True positives</b> will receive appropriately further necessary testing with CT or MRI, or contrast enhanced ultrasound (CEUS) and possibly treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False negatives</b> will be misdiagnosed and not receive appropriate treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True negatives</b> will not appropriately undergo unnecessary further testing with CT, MRI, CEUS, biopsy. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False positives</b> will inappropriately undergo further unnecessary testing with CT, MRI, CEUS biopsy. </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AFP (cut‐off 20 ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147</p> <p>(52144)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>59.8%</p> <p>(57.9% to 61.7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84.4%</p> <p>(82.3% to 86.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>802</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>b</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AFP (cut‐off 200 ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56</p> <p>(20452)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36% (31% to 41%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99% (98% to 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>940</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>c</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>693</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39</p> <p>(18792)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72%</p> <p>(63% to 79%),</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94% (91% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>893</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>very low <sup>d</sup> </p> <p>⨁◯◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combination of AFP (cut‐off 20 ng/mL) and US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p>(5044)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96%</p> <p>(88% to 98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85%</p> <p>(73% to 93%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>low <sup>e</sup> </p> <p>⨁⨁◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup> We chose for exemplification two values of HCC prevalence: 5% for a population at low risk (compensated advanced chronic liver disease and chronic viral hepatitis) <a href="./references#CD013346-bbs2-0607" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gatroenterology2009;136(1):138-48.">Lok 2009</a> and 30% for a population with high risk, a median of the prevalence in the included cross‐sectional studies conducted in clinical cohorts. </p> <p><sup>b</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 24% to 90% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>c</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 4% to 83% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>d</sup> Downgraded by three levels: risk of bias, indirectness, and inconsistency. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum); inconsistency downgraded one level as for individual studies ranged from 28%to 100% and we could not explain the heterogeneity by study quality or other factors </p> <p><sup>e</sup>Downgraded by two levels: risk of bias, indirectness. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum). </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">'Summary of findings' table: diagnostic accuracy of AFP, US, and combination of AFP and US for the diagnosis of HCC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013346-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table: direct comparison of US, and combination of AFP and US</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Review question</b>: what is the diagnostic accuracy of the combination of alpha‐foetoprotein (AFP) and abdominal ultrasound (US) compared to US for the diagnosis of hepatocellular carcinoma (HCC) in adults with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Setting</b>: clinical setting (secondary or tertiary care setting) or surveillance programs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Study design</b>: prospective and retrospective cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Index tests</b>:abdominal ultrasound; combination of serum alpha‐foetoprotein (AFP) measurement with a cut‐off value of 20 ng/mL and abdominal ultrasound </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Target condition</b>: HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Reference standards</b>:the pathology of the explanted liver in case of transplantation;the histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up period of at least six months to exclude the presence of focal lesions non detected by the index test and synchronous lesions from the parenchyma surrounding the resected or biopsied area;typical characteristics on cross‐sectional multiphasic contrast CT or MRI, with a follow‐up period of at least six months in order to allow the confirmation of an initial negative result on computer tomography (CT) or on magnetic resonance imaging (MRI). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Limitations in the evidence</b> </p> <p><b>Risk of bias/ Applicability</b> </p> <p>‐ Participant selection: high/unclear risk of bias in 2 studies (33%)/ high concern 2 studies (33%) </p> <p>‐ Index tests: high/unclear risk of bias in 2 studies (33%)/ high concern no study</p> <p>‐ Reference standard: high/unclear risk of bias in 4 studies (67%)/ high concern 1 study (17%) </p> <p>‐ Flow and timing: high risk of bias in 6 studies (100%)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>Findings</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Implications in a hypothetical cohort of 1000 people</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index test</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies (participants</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sensitivity</b> </p> <p>(95% CI)</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative sensitivity (95% CI)</b> </p> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative specificity</b> </p> <p><b>(95% CI)</b> </p> <p><b>P value</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed prevalence of hepatocellular carcinoma (HCC)<sup>a</sup> </b> </p> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True positives</b> <br/>will receive appropriately further necessary testing with CT or MRI, or contrast enhanced ultrasound (CEUS) and possibly treatment . </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False negatives</b> <br/>will be misdiagnosed and not receive appropriate treatment. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>True negatives</b> <br/>will not appropriately undergo unnecessary further testing with CT, MRI, CEUS, biopsy </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>False positives</b> <br/>will inappropriately undergo further unnecessary testing with CT, MRI, CEUS biopsy. </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6 (5044)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>76% (56% to 89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1.28 (1.03 to 1.539</p> <p>P = 0.014</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93% (80% to 96%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0.94, (0.87 to 1.01)</p> <p>P = 0.102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>883</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>low<sup>b</sup> </p> <p>⨁⨁◯◯</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>651</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combination of AFP (cut‐off 20 ng/mL) and US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96% (88% to 98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85% (73% to 82%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p><sup>a</sup> We chose for exemplification two values of HCC prevalence: 5% for a population at low risk (compensated advanced chronic liver disease and chronic viral hepatitis) <a href="./references#CD013346-bbs2-0607" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gatroenterology2009;136(1):138-48.">Lok 2009</a> and 30% for a population with high risk, a median of the prevalence in the included cross‐sectional studies conducted in clinical cohorts. </p> <p><sup>b</sup>Downgraded by two levels: risk of bias, indirectness. Risk of bias downgraded one level because all studies were judged at high risk of bias; indirectness downgraded one level as we considered most studies to have concern regarding applicability mainly in relation to the population (including disease spectrum) </p> <p><b>GRADE certainty of the evidence</b> </p> <p><b>High:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p>The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">'Summary of findings' table: direct comparison of US, and combination of AFP and US</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013346-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Guideline recommendations for surveillance for hepatocellular carcinoma</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>GUIDELINE</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>INDICATION TO SURVEILANCE</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>TEST</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>INTERVAL</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Association for the Study of Liver Disease (AASLD; (<a href="./references#CD013346-bbs2-0591" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.)2018;67:358-80.">Heimbach 2018</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound alone or plus AFP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>European Association for the Study of the Liver with European Organization for Research and Treatment of Cancer (EASL‐EORTC; (<a href="./references#CD013346-bbs2-0585" title="European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2012;56(4):908-43.">EASL‐EORTC 2012</a>; <a href="./references#CD013346-bbs2-0584" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: managementof hepatocellular carcinoma. Journal of Hepatology2018;69:182-236.">EASL 2018</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis in Child Pugh stages A and B; cirrhosis in Child C stage awaiting liver transplantation; non‐cirrhotic hepatitis B virus (HBV) carriers with active hepatitis or family history of HCC; non‐cirrhotic chronic hepatitis C with advanced liver fibrosis stage 3 (F3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> <p>3 to 4 months: people with a nodule less than 1 cm or after resection or loco‐regional therapies </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asian Pacific Association for the Study of the Liver (APASL; (<a href="./references#CD013346-bbs2-0613" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11:317–70.">Omata 2017</a>)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cirrhosis and chronic HBV infection at risk of HCC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound with serum AFP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>AFP:</b> alpha‐foetoprotein; <b>HCC:</b> hepatocellular carcinoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Guideline recommendations for surveillance for hepatocellular carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013346-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 20 ng/mL</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (81% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.133</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% (52% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (84% to 91%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (54% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86% (81% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.828</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% (59% to 71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (81% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.264</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (56% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (82% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (51% to 70%)*</p> <p>57% (50% to 63%)**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (84% to 90%)*</p> <p>83% (74% to 90%)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (54% to 65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (83% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (50% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (85% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (80%to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (54% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (71% to 89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (47% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (84% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.147</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (81% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (59% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (80% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (49% to 60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% (86% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61% (48% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (64% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.909</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56% (51% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (81% to 91%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (58% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (77% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.832</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (82% to 87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (55% to 63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (83% to 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.694</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (57% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (81% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (52% to 67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86% (82%to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.746</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% (55% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (77% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% (58% to 62%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (82% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>* <a href="./references#CD013346-bbs2-0107" title="HallagerS , LadelundS , KjaerM , MadsenLG , BelardE , LaursenAL , et al. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study. Journal of Viral Hepatitis2018;25(1):47-55. ">Hallager 2018</a> ; ** <a href="./references#CD013346-bbs2-0159" title="LiuXY , FanYC , GaoS , ZhaoJ , ChenLY , LiF , et al. Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma. Neoplasma2017;64(5):745-53. ">Liu 2017</a> </p> <p>§ Model failed to converge</p> <p><b>HCC</b>: hepatocellular carcinoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 20 ng/mL</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013346-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 200 ng/mL</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (31% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% (30% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.874</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39% (28% to 51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (27% to 58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.713</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35% (30% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28% (15% to 47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.336</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (33% to 42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (28% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (99% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (28% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.020</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% (21% to 35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% (29% to 40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98% (97% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53% (39% to 66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% (16% to 48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.805</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (32% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (32% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.995</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34% (18% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (96% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (8% to 85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (82% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.931</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27% (12% to 50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% (24% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.140</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (32% to 43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37% (29% to 46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.705</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32% (26% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98% (98% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42% (31% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (99% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24% (19% to 29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (97 to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36% (31% to 41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>HCC</b>: hepatocellular carcinoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heterogeneity and sensitivity analyses for alpha‐foetoprotein (AFP) cut‐off value around 200 ng/mL</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013346-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Heterogeneity and sensitivity analyses for ultrasonography (US)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (63% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (64% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (77% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.737</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71% (62% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (92% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (60% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (58% to 82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (70% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (92% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.091</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67% (54% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (88% to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (60% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (73% to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.186</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57% (45% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (58% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (85% to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (54% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (92% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (62% to 82%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (88% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (61% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (89% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.898</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69% (57% to 79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (91% to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (75% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82% (60% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.088</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66% (52% to 77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (91% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (64% to 91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (84% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.379</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55% (41% to 69%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (93% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (64% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (89% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% (57% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (90% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (58% to 91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (79% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% (33% to 68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (83% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.346</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (52% to 88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (82 to 98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US positivity criteria predefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (63% to 83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (89% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterpretable test results reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (71% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76% (71% to 81%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72% (64% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% (91% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>OLT</b> : orthotopic liver transplantation; <b>HCC</b>: hepatocellular carcinoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Heterogeneity and sensitivity analyses for ultrasonography (US)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013346-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Heterogeneity and sensitivity analyses for the combination of alpha‐foetoprotein (AFP) (cut‐off 20 ng/mL) and ultrasonography (US)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Specificity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cross‐sectional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (84% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91% (75% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.578</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>retrospective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (83% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77% (66% to 85%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>before 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (44% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (69% to 89%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.703</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>after 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (89% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (69% to 95%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cirrhosis &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (83% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (67% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> <p>90% (77% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (79% to 94%)</p> <p>83% (79% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> <p>82% (81% to 84%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (78% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% (76% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC prevalence &gt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (79% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (68% to 97%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>clinical suspect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (78% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.289</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>surveillance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97% (92% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (70% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% (84% to 99%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (72% to 96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>biopsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (78% to 93%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>other reference standard</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93% (86% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (72% to 95%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &lt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87% (79% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>viral &gt; 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> <p>82% (81% to 84%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &lt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (83% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74% (67% to 80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>*§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Child A &gt; 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99% (98% to 100%)</p> <p>91% (81% to 96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68% (66% to 71%)</p> <p>98% (96% to 99%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US positivity criteria predefined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% (77% to 97%)</p> <p>94% (71% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (79% to 87%)</p> <p>82% (81% to 84%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>§</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96% (88% to 98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85% (73% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>* Sparse and missing data. Meta‐analysis not conducted</p> <p>§ Model failed to converge</p> <p><b>OLT</b> : orthotopic liver transplantation; <b>HCC</b> : hepatocellular carcinoma; <b>US</b>: ultrasonography </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Heterogeneity and sensitivity analyses for the combination of alpha‐foetoprotein (AFP) (cut‐off 20 ng/mL) and ultrasonography (US)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/full#CD013346-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013346-tbl-0008"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 Alpha‐foetoprotein <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144570</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Ultrasound <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18792</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 US + AFP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5454</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 AFP cut‐off around 20 ng/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52144</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 AFP cut‐off around 200 ng/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20452</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 US + AFP cut‐off 20 ng/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5044</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 US for direct comparison AFP 20 ng/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6674</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013346.pub2/references#CD013346-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013346.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013346-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013346-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013346-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013346-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013346-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013346-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013346-note-0017">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013346-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013346-note-0012">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013346\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013346\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013346\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013346\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013346\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013346.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013346.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013346.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013346.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013346.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717245245"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013346.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717245249"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013346.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db3181baa9365',t:'MTc0MDcxNzI0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 